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Background and purposes: Citicoline, also known as CDP-choline (cytidine-5-
diphosphocholine), is a naturally-occurring endogenous nucleoside, which is one of the 
neuroprotective drugs that have been used as a therapy in stroke patients. However, 
the mechanisms through which it acts are not fully understood. In terms of analysis of 
the signalling mechanisms associated with citicoline-induced protection, it has been 
previously shown that citicoline may protect the ischemic neurons by suppressing 
caspase apoptotic pathway activation. Moreover, preliminary in vitro studies have 
shown that citicoline induces angiogenesis (the formation of new blood vessels from 
pre-existing capillaries). However, the possible beneficial effects of citicoline treatment 
on revascularization and angiogenesis after stroke have not been fully examined. The 
present study was designed to investigate the key signalling mechanisms through which 
citicoline modulates apoptosis and angiogenesis-associated with stroke recovery.  
Methods: An analysis of citicoline signalling pathway was studied from phospho-protein 
screening array done by Kinexus. In vitro angiogenesis assays: migration, proliferation 
and differentiation into tube-like structures in Matrigel™ ™ assays, have been used in 
human brain microvessel endothelial cells (hCMEC/D3). Western blotting was 
performed on protein extraction from hCMEC/D3 stimulated with citicoline. Analysis of 
apoptosis by flow-cytometry in hCMEC/D3. A hypoxia induced apoptosis assay was 
performed by seeding hCMEC/D3 on to glass coverslips in serum poor medium. 
Quantification of apoptotic cells were carried out under fluorescence microscopy using a 
combination of propidium iodide and DAPI stain solution. Apoptotic pathways in 
hCMEC/D3 stimulated with citicoline were examined by indirect immunofluorescence 
and real time PCR. Pharmacological inhibitor of Her2 (GW2974) was used to 
investigate the angiogenic signalling pathway by western blotting and Matrigel™  assay 
in hCMEC/D3 in the presence or absence of citicoline.   
Results: Kinexus results showed an over-expression of ASK-1, HER2, IRS-1 and Jun 
and inhibition of Hsp27, Integrin alpha4, MEK1 (MAP2K1) and Histone H2B Ser14 
proteins. Citicoline induced EC migration and differentiation in poly-l-lysine and 
Matrigel™ . Using microarray screening, the Histone H2B (Ser14) appeared to be the 
main phosphor-protein expression blocked by citicoline in hCMEC/D3, and the 
expression of tyrosine-protein kinase erbB-2 receptor (Her2) appeared to be induced by 
citicoline in hCMEC/D3. Treatment with the Her2 inhibitor (GW2974) totally blocked 
citicoline induced endothelial tube formation in EC, whereas treatment with GW2974 in 
combination with FGF-2 did not affect FGF-2 induced endothelial tube formation. In 
cultured hCMEC/D3 treatment with GW2974 inhibited citicoline induced phosphor-Erk 
expression, whereas treatment with GW2974 in combination with FGF-2 did not affect 
FGF-2 induced phosphor-Erk expression. However, Citicoline had no mitogenic effects 
on hCMEC/D3. Phspho-Caspase-3 and phosphor-H2B (Ser14) expression were 
inhibited by citicoline in hCMEC/D3 whereas the expression of phosphor-Her2 and 
6 | P a g e  
 
phosphor-Erk expression were increased. Moreover, citicoline treatment showed a 
decrease in number of apoptotic cells (positive PI staining) in hypoxia induced apoptosis 
compared to untreated cells. In cell migration assay, treatment with citicoline 
significantly increased cells migration in hCMEC/D3 compared to untreated cells on 
hypoxia conditions. Detection of apoptotic cells by flow cytometry showed inconclusive 
results in both treated and untreated hCMEC/D3. Results from indirect 
immunofluorescence showed a significant increase in active Caspase-3 and H2B 
(Ser14) expression in citicoline treated cells in comparison with untreated cells in 
hypoxia conditions. Results from PCR showed inhibition of pro-apoptotic genes 
including BNIP3, BNIP3L, caspase 4, caspase 8, caspase 9, CIDEB, DFFA, LTBR, 
TP53BP2, TRADD, and TRAF3 with citicoline treatment. They also show an over-
expression of a number of anti-apoptotic genes including NAIP, NOD1, TNFRSF25, and 
TP53. 
Conclusions: A screening of phosphor-protein expression revealed that citicoline 
specifically over-expressed Her2 which demonstrated that citicoline plays a key role in 
Her2 induced angiogenesis. Blocking of Her2 pathway inhibited the formation of tube-
like structures in citicoline treated cells and therefore citicoline induces angiogenesis 
through Her2 pathway, and that is important in terms of understanding the molecular 
pathway in which citicoline acts as a pro-angiogenic molecule in tissue remodelling after 
stroke. Citicoline decreased active caspase-3 and H2B (Ser14) expression, and positive 
PI staining which demonstrates a protective effect of citicoline against endothelial cells 
apoptosis. Citicoline also improved cell surivial by decreasing the expression ofBNIP3, 
BNIP3L, caspase 4, caspase 8, caspase 9, CIDEB, DFFA, LTBR, TP53BP2, TRADD, 
and TRAF3 genes and inducing the expression ofNAIP, NOD1, TNFRSF25, and TP53. 
Citicoline treatment significantly promotes wound healing in stroke mimicking conditions 
(hypoxia). Thus, the therapeutic properties of citicoline has the potential to promote 
vessel formation whilst reducing the risk cell death from hypoxic stress following 
ischemic stroke.    
Key words: Citicoline, angiogenesis, apoptosis, stroke. 
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General introduction. 
 
Citicoline: 
Citicoline Structure: 
Cytidine 5'-diphosphocholine, CDP-choline, or citicoline is a crucial intermediate in the 
biosynthesis of structural phospholipids in cell membranes, specifically 
phosphatidylcholine. CDP-choline (C14H26N11O4P2) is a polarised molecule with a 
molecular weight of 488.33 g/mol. The monosodium salt of CDP-choline (MW=510.31) 
is a white, crystalline, spongy, very hygroscopic powder that is soluble in water and 
almost insoluble in alcohol. Citicoline is the International Nonproprietary Name (INN) for 
cytidine diphosphate-choline (CDP-Choline) and cytidine 5'-diphosphocholine. Citicoline 
has been extensively studied in numerous countries in different parts of the world and 
has more than 70 trade names. The use of CDP-choline (citicoline) as a therapy to 
enhance endogenous phosphatidylcholine synthesis, is an attractive concept, because 
it might speed up the replacement or repair of cellular membranes which could play a 
critical role in the function of numerous physiological processes. It could have a 
potential medicinal efficacy in numerous diseases in which membrane disorder, 
dysfunction, or degeneration results in cellular and tissue ischemia and necrosis. 
Following administration by both the oral and parenteral routes, CDP-choline is 
hydrolysed to choline and cytidine. Orally administered CDP-choline is efficiently 
absorbed, and therefore, bioavailability by the oral route is almost the same as the 
intravenous route. After absorption, citicoline is extensively dispersed throughout the 
body, crosses the blood-brain barrier and reaches the central nervous system (CNS), 
where it is incorporated into the membrane and microsomal phospholipid fraction. 
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Citicoline increases brain metabolism, activates biosynthesis of structural phospholipids 
of neuronalmembranes, and regulates the levels of different neurotransmitters. In the 
brain, choline is metabolized to phosphorylcholine, which then integrates with CTP to 
produce intracellular CDP-choline which is subsequently converted to 
phosphatidylcholine. In the brain, Choline is also converted to acetylcholine especially in 
cholinergic neurons. Choline from neuronal membrane phosphatidylcholine is used for 
the synthesis of acetylcholine in case of depletion in acetylcholine levels in the brain 
(Secades & Lorenzo, 2006, Rema et al., 2008, Weiss, 1995). 
 
Figure 1. Citicoline Structure. It is composed of ribose, pyrophosphate, cytosine and choline. It 
is organized in two moieties, cytidine and choline, that are linked by a diphosphate bridge 
(Jamboua et al., 2009). 
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Citicoline Metabolism. 
 
Exogenous CDP-choline when administered orally or by injection to rats, is fully 
metabolized to produce two intermediates; choline and cytidine. These intermediates 
pass through the circulation, cross the blood brain barrier and are partially altered to 
acetylcholine phosphocholine, and CTP. Previous studies demonstrated that, in humans 
as in rats, the metabolism of exogenous CDP-choline raises plasma levels of cytidine as 
well as choline (Wurtman et al., 2000). Cytidine and choline have essential roles in 
phospholipids production involved in membrane formation and repair. They also play 
part in such important metabolic functions as the production of nucleic acids, proteins, 
and acetylcholine. When citicoline is orally administered, it is hydrolysed in the intestine, 
absorbed rapidly as choline and cytidine, resynthesized in liver and other tissues, and 
finally mobilized in CDP-choline synthetic pathways (Weiss, 1995). In animals, choline 
can be obtained from the diet and via de novo biosynthesis: choline is produced through 
the conversion of phosphatidylethanolamine (PE) to phosphatidylcholine (PC) which is 
catalysed by an enzyme called phosphatidylethanolamine N-methyltransferase (PEMT). 
Then choline can be produced from PC via the action of phospholipases (Li & Vance, 
2008). The two pathways of PC synthesis and break down are important to the cellular 
homeostasis and therefore disruption of PC homeostasis in mammalian cells leads to 
apoptosis. Choline is an important compound in PC synthesis as well as other major 
phospholipids, and an important neurotransmitter acetylcholine, and an essential 
nutrient that can be found in normal diet like, beef, liver, eggs, cauliflower, whole milk, 
grapes, etc. Mitogenic stimulations by growth factors or oncogenic transformation 
activate PLD-driven PC hydrolysis to yield choline and phosphatidicacid (PA). This type 
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of choline along with choline from external sources enters the Kennedy pathway 
(Janardhan et al., 2006). 
The process of choline transportation across the cell membrane is an important process 
that is highly regulated and associated with CDP-choline pathway and choline 
metabolism. Choline transporters play two roles including mainly choline uptake from 
the extracellular space and directing choline to mitochondria for degradation, cellular 
exit of choline in mammals, and betaine generation. Betaine is an osmolyte, which is 
used in the kidney to regulate physiological osmotic pressure. In the liver betaine is 
utilized in methyl group metabolism which is linked to PC synthesis via the PEMT 
reaction (Fagonea & Jackowski, 2013). 
Choline is a neutral molecule with a positive and a negative electrical charge (zwitterion) 
that is positively charged at certain pH, which requires transport systems to allow this 
amine to cross the phospholipid bilayer of cellular membranes. In higher eukaryotes, 
there are three types of transporters that mediate choline movement in and out of the 
membrane. Kinetic studies conducted using radiolabeled choline and inhibitors 
discovered three systems for choline transport including low-affinity facilitated diffusion, 
high-affinity, Na+-dependent transport, which are linked with the synthesis of 
acetylcholine in neurons, and intermediate-affinity, Na+-independent transport. 
However, choline transporter-like proteins have been recently identified. They include 
polyspecific organic cation transporters (OCTs) with low affinity for choline, high-affinity 
choline transporters (CHT1s), and intermediate-affinity choline transporter-like (CTL1) 
proteins. CTL1 is Na(+)-independent and sensitive to inhibition by the drug 
hemicholinium-3. The expression of genes associated with cell proliferation, 
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differentiation, and apoptosis, are affected by choline deficiency and it has been 
involved in liver dysfunction and cancer. Abnormalities in choline transport and 
metabolism have been associated with a number of neurodegenerative disorders such 
as Alzheimer's and Parkinson's disease (Michel & Bakovic, 2012, Michel et al., 2006). 
The Kennedy (CDP-choline) pathway and the phosphatidylethanolamine (PE) 
methylation pathway are the two pathways in which PC can be synthesized de novo in 
mammalian cells. In the CDP-choline pathway, there are three reactions: the first 
reaction is the ATP-dependent phosphorylation of choline, which is catalysed by an 
enzyme called choline kinase (CK) to form phosphocholine (P-Cho), and the byproduct 
ADP. The second reaction is considered to be the rate-limiting step of the Kennedy 
pathway, CTP:phosphocholinecytidylyltransferase (CCT) phosphoethanolamine and 
CTP to form the high-energy donor CDP-phosphocholine with the release of 
pyrophosphate. In the final reaction of the pathway, cholinephosphotransferase (CPT) 
transfers a phosphocholine group from CDP-choline to diacylglycerol (DAG) to form PC 
(Aoyama et al., 2004, Henneberry et al., 2001). 
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Figure 2. The CDP-choline pathway. nzymes: CK, choline kinase; CCT, 
phosphocholinecytidylyltransferase; CPT, cholinephosphotransferase; EK, ethanolamine kinase; 
ECT, phosphoethanolaminecytidylyltransferase; EPT, ethanolaminephosphotransferase 
(Gibellini & Smith, 2010). 
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Citicoline in Trials: 
 
There has been an increased recognition of citicoline as a neuroprotectant drug that 
may act both in early and late stages of ischemic damage, resulting in an escalation in 
experimental and clinical trials studying safety and efficacy of its use as a treatment for 
stroke. The neuroprotective properties that citicoline exhibits could be due to its ability to 
enhance PC synthesis in the injured brain. Citicoline increase membrane stability and 
promotes repair drives the synthesis of nucleic acids, proteins, acetylcholine, and other 
neurotransmitters; reduces the free radical formation; inhibits free fatty acid production 
and has anti-apoptotic effects (Sahota & Savitz, 2011). In a study, it was found that in 
normal rats treated daily with citicoline for 3 months, PC levels increased by 25%. 
Treatment with citicoline prior to an ischemic event decreased the loss of PC during 
ischemia. It also decreased the levels of arachidonic acid release and in part restored 
phospholipid loss after ischemia/1-day reperfusion. It has also been demonstrated to 
have inhibitory effects against phospholipase A2 activation. Phospholipase A2s (PLA2s) 
is a family of esterases that hydrolyze the sn-2 ester bond in phospholipids, producing 
free fatty acids and lysophospholipids. PLA2s play an important role in the signalling 
pathways of numerous cellular processes including inflammation. Reports demonstrate 
that PLA2s control cell damage caused by drug, chemical and ischemia/reperfusion. 
The role of PLA2s in apoptosis and ischemic cell death relies on the PLA2 isoform, the 
cell type, and the cause of injury. Citicoline may alter the levels of several lipids after 
ischemia and reperfusion. It has been previously reported that citicoline administered at 
0 and 3 hours after transient ischemia demonstrated significant neuroprotection, 
however treatment with citicoline after the first 2 doses showed greater protection. 
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These data suggest that citicoline has an effect in events beyond the first day of 
reperfusion that are important for its neuroprotective effects. Glutathione is one ofthe 
main endogenous antioxidant defence systems in the brain, and it plays important roles 
in antioxidant defence, nutrient metabolism, and regulation of cellular events (including 
gene expression, DNA and protein synthesis, cell proliferation and apoptosis, signal 
transduction, cytokine production and immune response, and protein glutathionylation). 
It can be produced through a process in which choline released from citicoline is 
metabolised to methionine which is in turn might be converted to glutathione through S-
adenosyl-L-methionine. Glutathione deficiency contributes to oxidative stress, which 
plays a key role in aging and the pathogenesis of many diseases including kwashiorkor, 
seizure, Alzheimer’s disease, Parkinson’s disease, liver disease, cystic fibrosis, sickle 
cell anemia, HIV, AIDS, cancer, heart attack, stroke, and diabetes. It has been reported 
that significant reduction in in glutathione and glutathione reductase activity after 
transient cerebral ischemia. Since oxidative damage contributes to neuronal death, 
citicoline may provide neuroprotection by increasing this defence system (Wu et al., 
2004, Cummings et al., 2000, Adibhatla et al., 2001).The CDP pathway has been a 
major target for drug development since the appearance of citicoline in the clinical field. 
This caused a development in dosage, administration techniques, and defining criteria 
of patients to which the therapies was given. It also created variations in clinical studies, 
including length of observation, severity of disturbance, and methodology of evaluation 
of the results. Citicoline is a commonly prescribed treatment for cognitive impairment in 
many European countries, especially when the clinical picture is mainly one of 
cerebrovascular disease (Fioravanti & Yanagi, 2000). 
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Citicoline is also involved in the biosynthesis of sphingolipids especially in that of 
sphingomyelin in the flowing reaction; ceramide reacts with citicoline to form 
sphingomyelin, the reaction is being catalysed by CDP choline 
ceramidephosphocholinetransferase. Sphingomyelin is an important component of 
neuronal membranes. Citicoline crosses the blood-brain barrier as cytidine and choline, 
which reach the brain and resynthesize citicoline in the cytoplasm. Citicoline is 
integrated widely in several brain areas. It also affects the levels of various 
neurotransmitters including dopamine, serotonin and noradrenaline. Citicoline was 
shown to elevate noradrenaline levels in the cortex and hypothalamus. Furthermore, it 
was demonstrated to elevate overall urinary excretion of 3-methoxy-4-
hydroxyphenilglycol, which reflects noradrenergic activity in rats and humans, indicating 
that citicoline increases noradrenaline release (Vasudevan et al., 2013, Platarasa et al., 
2000). 
Citicoline has the potential to improve endogenous brain plasticity and repair which may 
reduce acute brain damage and improve functional recovery in animal models of stroke, 
even when it is administered several hours after the ischemic event. Moreover, it has 
been demonstrated that citicoline affects different levels of the ischemic cascade, and a 
series of brain repair have been documented. It also have been reported that citicoline 
restores the activity of mitochondrial ATPase and membrane Na+/K + ATPase, and to 
accelerate reabsorption of cerebral edema in numerous experimental models 
(Overgaard, 2014). 
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Figure 3. The points where citicoline has been reported to have a pharmacologic effect in the 
ischemic cascade are marked in red (Overgaard, 2014). 
The initial properly designed clinical trials using citicoline in acute stroke patients 
demonstrated positive outcomes; however, the sample size of these studies was 
insufficient. In the United States, the clinical development of citicoline as a therapy of 
acute ischemic stroke started in the 1990s. The first US phase II to III trial was 
preformed to assess the effect of 3 doses (500, 1000, and 2000 mg/d) of citicoline 
against placebo. Treatment using citicoline at doses of 500 and 2000 mg/d showed 
significant improvement of neurological (National Institutes of Health Stroke Scale 
[NIHSS]), functional (Barthel Index [BI]), and global (modified Rankin Scale [mRS]) 
results in comparison with placebo 12 weeks after stroke onset. In the second study, 
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treatment with citicoline 500 mg displayed significant improvements in a subgroup 
ofpatients with moderate to severe strokes (baseline NIHSS ≥8) with regard to 
functional recovery (BI ≥95) compared with placebo (Dávalos et al., 2002). There are 
other numerous clinical trials conducted to examine the effect of citicoline, however the 
results were inconclusive. One of the main reasons behind the controversy on the 
effectiveness of citicoline is the variations in the drug administration in the clinics (oral 
versus intravenous), considering that only 0.2–2.0% of the administered citicoline 
reaches in the brain parenchyma, subject to the administration route. The polar nature 
of citicoline compromises the passing of the drug through the blood brain barrier (BBB). 
Thus, using alternative methods of citicoline administration to enhance its bioavailability 
in the brain parenchyma, would potentially improve the therapeutic effects of this drug in 
stroke treatment. One of these drug delivery systems is the use of liposome 
encapsulation. In a study using longitudinal MRI, volumes and edema in an animal 
model of stroke were measured. Nine- teen rats were subjected to permanent occlusion 
of the middle cerebral artery and treated with saline, intraperitoneal citicoline (500 
mg/kg), intravenous citicoline (48 mg/kg), and intra- venous liposome-encapsulated 
citicoline (48 mg/kg). Lesion volumes were measured by MRI at days 0, 1, 3 and 7 
following surgery. The results demonstrated that the therapeutic efficiency of citicoline 
has increased using encapsulation in liposomes. There was a 32% reduction of the 
infarct sizes at day 7, in comparison with controls where infarct sizes at day 7 increased 
by 39%, respect to values at day 0. Intravenously injected citicoline reduced infarct 
sizes by 9% while intraperitoneal citicoline increased the infarct sizes by 10%. Animals 
treated with citicoline, in all of the forms of delivery, displayed an insignificant reduction 
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of edema formation. There was a clear reduction in lesion volumes using liposome-
encapsulated citicoline at days 1, 3 and 7 following permanent stroke compared to 
control, citicoline I.P and I.V (Ramos-Cabrer et al., 2011). 
Moreover, citicoline can be used in combination with other treatments. In a study, the 
effects of citicoline were evaluated on the suppression of apoptotic processes after 
transient focal cerebral ischemia, either administered alone or combined with 
hypothermia. To conduct this study, middle cerebral artery occlusion (MCAo) was 
performed for 2 hours on Sprague-Dawley (SD) rats using intraluminal thread insertion. 
There were five groups with different treatments including, sham-operated, saline, 
citicoline (400 mg/kg intraperitoneal.), hypothermia (34 ± 1 °C) and citicoline + 
hypothermia group. For 24 hours, all rats were reperfused, and after transcardiac 
perfusion, immunohistochemical studies were conducted for markers of apoptosis. The 
saline group exhibited lower Bcl-2 immunostaining score compared to the citicoline, 
hypothermia and citicoline + hypothermia groups. Bcl-2 family members acting as 
oncogenic and anti-death molecules regulate various homeostatic, developmental and 
disease progressions. Anti-apoptotic protein bcl-2 binds to beclin 1 under non-stress 
conditions and inhibits autophagy. In the sham-operated group, the Bcl-2 
immunostaining score was lower compared to compared to the citicoline, hypothermia 
and citicoline + hypothermia groups. There was higher expression of caspase-3 proteins 
in the saline group compared to citicoline + hypothermia group. Cysteinyl aspartate-
specific proteases (caspases) include a dozen of distinct enzymes that are involved in 
inflammation, activation, or execution of the apoptotic biochemical events. They play an 
important in role in programmed cell death, which occurs physiologically through 
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defined morphological and biochemical features, namely apoptosis, necroptosis, or 
programmed necrosis. Bax proteins were also increased in saline group compared to 
citicoline + hypothermia group and inhypothermia group compared to citicoline + 
hypothermia group. Bax is a proapoptotic member of the Bcl-2 family, which is normally 
found in the cytosol and is trans-located to mitochondria when cells are under apoptotic 
stress. Bax induces opening the mitochondrial permeability transition pore, which 
stimulates the release of cytochrome C followed by an apoptotic cascade. In the saline 
group, significant differences in caspase-9 immunostaining results were revealed 
compared to citicoline + hypothermia group; citicoline group compared to citicoline + 
hypothermia group; and hypothermia group compared to citicoline + hypothermia group. 
Therefore, by inhibiting apoptotic pathways using citicoline in combination with 
hypothermia is more effective than either used alone in ameliorating cerebral damage 
after transient focal ischemia (Sahina et al., 2010, Sawadaa et al., 2014, Nicholson et 
al., 2013, Baspinara et al., 2014). 
Citicoline has also been used in combination with lithium, which is the first drug to show 
significant upregulation of Bcl-2 in rodent brain in vivo and cells with human neuronal 
phenotype. In a study, citicoline in combination with lithium (Li−) have been 
demonstrated to promote retinal ganglion cell (RGC) survival and axon renewal in vitro. 
A model of both brain axonal injury and particular aspects of the glaucomatous 
degeneration of RGC, which is an optic nerve crush (ONC) model, was used to 
measure the level of protection provided by citicoline and lithium to RGC and to 
determine whether their effects are regulated by increased expression of Bcl-2. The 
study was conducted using Adult rats (6–12 per group) that were subjected to ONC 
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accompanied by a contralateral sham operation. The treatments included intraperitoneal 
injection with either vehicle, citicoline sodium (1 g/kg daily for up to 7 days and 300 
mg/kg daily afterwards), lithium chloride (30 mg/kg daily), or both drugs combined. 
Fluorogold was injected bilaterally into superior colliculi 1, 5 or 19days after ONC. 2 
days after tracer injection, stained cells were counted under a fluorescence microscope. 
The effects of treatments on expression of Bcl-2 in retinas were measured by 
immunohistochemistry in a separate set of experiments. The results showed a 
progressive reduction of RGC density after crush in vehicle-treated animals. In 
citicoline-treated animals, the reduction in RGC density was attenuated 1 week and 3 
weeks after the crush. RGC protection was even more prominent in the lithium-treated 
group. The result from animals treated with both drugs was approximate to that 
achieved by lithium treatment. Bcl-2 immunoreactivity was seen mostly in retinal 
ganglion cells. In the lithium and citicoline group as well as in animals treated with the 
combination of both drugs, there was an increase in Bcl-2 immunoreactivity. Citicoline 
and lithium were demonstrated to be protective of RGC and their axons in vivo against 
delayed degeneration triggered by the ONC. Therefore, the increase in Bcl-2 expression 
triggered by both drugs could be the cause of the observed retino-protective action 
(Schuettaufa et al., 2006, Goodwin & Jamison, 2007). 
In another study, the combination of rtPA with citicoline as compared to either alone as 
monotherapy, and whether the neuroprotector should be administered before or after 
thrombolysis to achieve a greater decrease of ischemic brain damage was tested in a 
rat embolic stroke model. Recombinant tissue plasminogen activator (rtPA) is an 
approved drug, that is administered on stroke patients and it works by dissolving 
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thrombi obstructing cerebral blood flow. The aim of the study was to test if combining 
reperfusion mediated by thrombolytics with pharmacological neuroprotection aimed at 
inhibiting the physiopathological disorders responsible for ischemia-reperfusion 
damage, could offer a better treatment of ischemic stroke. The study was conducted 
using one hundred and nine rats four were sham-operated andthe rest embolized in the 
right internal carotid artery with an autologous clot and divided among 5 groups 
including control, iv rtPA 5 mg/kg 30 min post-embolization, citicoline 250 mg/kg ip ×3 
doses, 10 min, 24 h and 48 h post-embolization, citicoline combined with rtPA following 
the same pattern, rtPA combined with citicoline, with a first dose 10 min after 
thrombolysis. To evaluate ischemic brain damage, numbers of factors were considered 
including death, neurological score, size of ischemic lesion and neuronal death 
(TUNEL) after 72 h and plasma levels of IL-6 and TNF-α. Compared with controls, the 
use of citicoline after thrombolysis produced the greatest reduction of mortality caused 
by the ischemic lesion, infarct volume, number of TUNEL positive cells in striatum and 
plasma levels of TNF-α at 3 h and 72 h. rtPA induced reperfusion displayed an 
insignificant decrease of infarct size and neuronal death, although it reduced mortality 
due to brain damage, an increase in the risk of fatal bleeding was observed. Citicoline 
as monotherapy only produced a significant reduction of neuronal death in striatum. The 
combination of citicoline before rtPA did not add any benefit to rtPA alone. The 
superiority of the combined treatment with rtPA followed by citicoline suggests that early 
reperfusion should be followed by effective neuroprotection to prevent ischemia-
reperfusion injury and improve the level of protection of the tissue at risk (Alonso de 
Leciñana et al., 2006, Ryou et al., 2013).  
27 | P a g e  
 
Another study was conducted to analyse the effects of citicoline in staurosporine-
induced cell death in human SH-SY5Y neuroblastoma cells. The results showed that 
citicoline decreases apoptosis induced by 100 nMstaurosporine for 12 h in SH-SY5Y 
cells. Pre-treatment of 60 mM citicoline for 24 h after staurosporine stress, yield a higher 
reduction in apoptosis. Furthermore, glutathione redox ratio reduced after staurosporine 
stress was restored after citicoline treatment. When citicoline wasadded to the cell 
culture 24 hr before the addition of staurosporine, the expression levels of active 
caspase-3 and cleaved PARP induced by staurosporine were inhibited by the action of 
citicoline. These results show that citicoline affects the staurosporine-induced apoptosis 
cell-signalling pathway by interacting with the glutathione system and by inhibiting 
caspase-3 in SH-SY5Y human neuroblastoma cells (Barrachina et al., 2002). 
In combination with levodopa, citicoline has been used as a therapeutic agent in the 
treatment of Parkinson's disease (PD). Levodopa is a precursor of dopamine and 
norepinephrine, and is one of the most effective symptomatic treatment options for 
Parkinsonism with a preferred safety and tolerability profile. In a study, the effects of 
citicoline was evaluated by using validated in vivo and in vitro models. Citicoline plays a 
neuro-protective role in 6-OHDA-treated SH-SY5Y neuroblastoma cells and following 6-
hydroxydopamine (6-OHDA)-induced neurodegeneration. 6-Hydroxydopamine (6-
OHDA) is a selective catecholaminergic neurotoxin extensively used to examine the 
pathogenesis and progression of PD. Citicoline also increased the levels of reduced 
glutathione (GSH), a major antioxidant agent, in 6-OHDA-treated SH-SY5Y 
neuroblastoma cells. Furthermore, citicoline (500 mg/kg i.p.) administered for 7 days 
improved functional behaviour by significantly decreasing the number of apomorphine-
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induced contralateral rotations in 6-OHDA rats. Finally, citicoline considerably 
decreases substantia nigra (SN) dopaminergic cell dropout and tyrosine hydroxylase 
immunoreactivity in the ipsilateral striatum in rats injected intrastriatally with 6-
hydroxydopamine (6-OHDA) (Noack et al., 2014, Barrachina et al., 2003). 
Citicoline has also been a subject of interest in the search for a combination of 
treatments with corresponding effects that could act at different stages in theischemic 
cascade. In an experiment, the effects of nimodipine, a dihydropyridine that blocks L-
type Ca2+ channels, in combination with citicoline have been tested in a rat model of 
reversible focal cerebral ischemia. The method of drug delivery involved intracarotid 
injection of citicoline and nimodipine to the ischemic cerebral tissue, prior to blood 
recirculation. When using an intravenous way, the efficiency of the treatment would be 
obstructed due to an inadequate perfusion in the ischemic zone. Nevertheless, the drug 
therapy reaches the ischemic area in a fast, concentrated and effective way when using 
an arterial route. The results showed that intracarotid injection of nimodipine in order to 
permeate the ischemic cerebral tissue just before recirculation or regular administration 
of citicoline by an i.p. route in order to decrease the harmful effects caused by cell 
membrane damage, during either ischemia or reperfusion, reduced infarct volume in an 
animal model of temporary focal cerebral ischemia with complete reperfusion and 7 
days of survival. Moreover, the combination of both drugs caused a greater reduction in 
infarct volume, compared with when either drug was given independently. Similarly, this 
combined treatment produced a higher reduction in apoptotic cell death and increased 
Bcl-2 expression in the inner boundary zone of the infarction 3 days after reperfusion 
(Sobrado et al., 2003). 
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In a study, the neuroprotective effect of citicoline on experimental models of KA-induced 
retinal damage was evaluated. KA is a structural analogue of l-glutamate and an agonist 
of ionotropic KA receptors. Intravitreal injection of kainic acid (KA) triggers rapid and 
selective lesions in the inner retina of rats with the photoreceptor cell-sparing , it is well 
established that glutamate receptor-related neurotoxicity can be induced by NMDA (N-
methyl-d-aspartic acid) and KA. Exposure to high concentrations of glutamate and 
glutamate analogues induces neuronal damage followed by cell loss in retinas 
stimulating the activation of NMDA receptors or KA/AMPA (kainic acid/a-amino-3-
hydroxy-5-methyl isoxazole-4-propionic acid) receptors. Citicoline treatment twice daily 
for 7 day inhibited the thinning of the inner retinal layers resulting from KA-injection and 
the degradation of the immune-reactivities of retinal choline acetyltransferase (ChAT), 
which is a key constituent of cholinergic neurons required for acetylcholine (ACh), and 
tyrosine hydroxylase (TH), which is the rate-limiting enzyme in the biosynthesis of the 
catecholamines dopamine, noradrenaline, and adrenaline (Lévesque & Avoli, 2013, 
Park et al., 2005, Dickson & Briggs, 2013). 
Stroke: 
Stoke is general term that refers to a focal neurologic event that is severe in onset and 
may have a vascular cause, etiology, or relevance. There are numerous terms that 
could be used to specify stroke depending on the type or the location of stroke such as 
hemorrhagic stroke, ischemic stroke, lacunar stroke, embolic stroke, young stroke, 
thrombotic stroke, spinal cord stroke, venous stroke, brain-stem stroke, and cerebellar 
stroke (Wityk & Llinas, 2007). It is estimated that stroke is the cause of 9% of deaths 
and is the second foremost cause of mortality around the world. Currently there are an 
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estimated 5.7 million stroke deaths which by 2030 is expected to increase to 7.8 million. 
It is expected that in low-income and middle-income countries most stroke mortality 
(87%) will take place. In developing countries, a rise in stroke mortality is equivalent to 
an increase in chronic stroke disease burden of almost 50% of total disease burden in 
the past 10 years. These tendencies could be related to the aging population and 
changes in cardiovascular disease risk factor profiles which contribute to early death 
(Bornstein, 2009). Previous predictions indicated that there would be a 30% increase in 
numbers of patients suffering a first-ever stroke in the UK between I983 and 2023, 
therefore increasing the demand on stroke medical facilities. Although there is a recent 
reduction in the rate of stroke incidence, there is an increase in the number of aging 
populations and the general burden of stroke which is likely to increase because of the 
rise in prevalence. Recent research demonstrates that survival after stroke is 
increasing, however patients could live with the consequences which can have 
significant effects on their lifestyle. It is important to improve stroke survival rate and 
decrease disabilities through medical interventions (Williams et al., 2010). 
Risk factors for a first stroke may be categorised according to whether they are: (I) 
uncontrollable; (2) well recorded and controllable, and (3) less well recorded or 
potentially controllable. The uncontrollable risk factors include: age, gender, family 
history, low birth weight and race. Well-documented and modifiable risk factors include: 
cardiovascular disease, coronary heart disease, heart failure, peripheral arterial disease 
hypertension, tobacco smoking, diabetes mellitus, asymptomatic carotid stenosis, atrial 
fibrillation, sickle cell anaemia, dyslipidaemia, high total cholesterol, low high-density 
lipoprotein cholesterol, dietary factors ( sodium intake >230O mg, potassium intake 
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<4,70O g), obesity, lack of physical exercise and postmenopausal hormone 
replacement therapy. Less-well recorded or potentially controllable risk factors include: 
metabolic syndrome, alcohol abuse, hyperhomocysteinemia, drug abuse, 
hypercoagulability, oral contraceptive use, inflammatory processes, migraine, high 
lipoprotein (a), high lipoprotein-associated phospholipase A2 and Sleep apnoea (Binder 
et al., 2012). Hypertension is one of the most important stroke risk factors. As blood 
pressure (BP) increases above 115/75 mm Hg the risk of stroke increase. BP values 
above the optimal rate of (<120/80 mm Hg) are associated with an increased stroke risk 
in males and femalesequally and for both fatal and nonfatal strokes. However, 
hypertension prevalence is higher in women at older age which could be due to women 
having a longer life expectancy than men. This could be the reason behind the overall 
higher stroke incidence in women than in men, because women account for 60% of all 
stroke events (Gorgui et al., 2014). 
Another major stroke risk factor is diabetes mellitus. Diabetes mellitus is a group of 
metabolic disorders characterized by hyperglycemia caused by abnormalities in insulin 
secretion, insulin action, or both. The chronic hyperglycemia of diabetes is associated 
with long-term damage, dysfunction, and failure of various organs, mainly the eyes, 
kidneys, nerves, heart, and blood vessels. It is increasingly common and it is an 
independent risk factor for ischaemic stroke by approximately doubling the risk. There 
are currently almost 2 million diabetics in the UK with an increase of 500,000 over the 
last 10 years. In the past 40 years, the prevalence of type 2 diabetes has doubled from 
4 to 8 per cent in the USA. In China the prevalence in adults has tripled from 1 to 3.2 
per cent between 1980 and 1996, and on other parts of Asia the increase is even more 
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worrying with rates increasing three-to fivefold in countries such as Thailand and 
Indonesia in the past 3 decades. Diabetes is usually associated with hypertension and 
higher blood cholesterol levels, and therefore it particularly increases the risk of 
vascular disease. Studies adjusting for these other risk factors still found that there is a 
two-fold increase in the risk of stroke in the presence of diabetes. Therefore, the rapid 
increase in obesity, and therefore in type 2 diabetes, will increase the risk of stroke. 
Diabetes possibly causes 10-20 per cent of all strokes (American Diabetes Association, 
2008, Lindley et al., 2008). 
There are two main types of stroke: haemorrhagic stroke ischemic stroke. 
Haemorrhagic stroke refers to bleeding in the skull, either into the brain or into thefluid 
around the brain. The second main type of stroke is called ischemic, which refers to a 
blockage of blood supply to the brain. Emia is a suffix that always refers to blood. 
Haemorrhage and ischemia are completely opposite to each other. Haemorrhage is 
characterized by excess amount of blood inside the skull. In ischemia, there is 
insufficient blood supply to support continued normal functioning of the effected brain 
tissue. Brain ischemia is much more common than haemorrhage and about four strokes 
out of every five are ischemic (Caplan, 2010). 
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Figure 4. A representation of the two major types of stroke (Heart and Stroke Foundation, 
2014). 
Ischemic stroke can be subdivided into three categories: thrombosis, embolism, and 
decreased systemic perfusion. Thrombosis is a term that refers to an obstruction of 
blood supply due to a localized occlusive process within one or multiple blood vessels. 
The lumen of the vessel is narrowed or occluded by a change in the vessel wall or by 
the formation of superimposed clot. Embolism refers to the formation of material in a 
different location within the vascular system blocking an artery, and therefore stopping 
blood flow. Blockage can be transient or may continue for hoursor days before moving 
distally. In comparison to thrombosis embolic luminal blockage is not caused by a 
localized process originating within the blocked artery. The material causing the 
blockage, arises proximally mainly from the heart; from major arteries such as the aorta, 
carotid, and vertebral arteries; and from systemic veins. Decreased systemic perfusion 
refers to restricted blood flow to brain tissue that is caused by low systemic perfusion 
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pressure. The most common causes are cardiac pump failure which is most often due 
to myocardial infarction or arrhythmia and systemic hypotension which is caused by 
blood loss or hypovolemia (Caplan, 2009). 
The main cause of haemorrhagic stroke is primary intracerebral haemorrhage from a 
spontaneous rupture of small vessels, which accounts for approximately 80% of 
haemorrhagic strokes, and is caused mainly by unmanaged high blood pressure. 
Subarachnoid haemorrhage accounts for about 50% of haemorrhagic strokes, and is a 
result of a rupture in the intracranial aneurysm caused by a weakening in the arterial 
wall. Another common cause of intracerebral haemorrhage in the elderly is cerebral 
amyloid angiopathy, which results from a damage caused by the deposit of beta-
amyloid protein in the small and medium-sized blood vessels of the brain (Smeltzer et 
al.(, 2010). 
It is often difficult to differentiate between ischemic stroke and haemorrhagic stroke 
because they have similar symptoms. It is also difficult to distinguish between 
hypoglycaemia and stroke because hypoglycaemia can produce focal neurological 
symptoms that resemble those of stroke. However, hypoglycaemia should be ruled out 
in all cases of suspected stroke, especially in known diabetics. Brain tumours and other 
intracranial masses such as subdural hematomas can cause transient neurological 
deficits and other stroke like symptoms. Headache is uncommonsymptom of ischemic 
stroke, but rather more common in haemorrhagic stroke. Early loss of consciousness, 
vomiting, and severely elevated blood pressure may also be symptoms of haemorrhage 
stroke (Popp, 2011). 
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The pattern of stroke symptoms occurs can be determined by the location of the stroke. 
One typical symptom of ischemic stroke is the absence of function such as loss of vision 
in a single eye or in an entire hemifield, numbness in part of the body, weakness or 
paralysis on one side of the body. A patient suffering from an intracerebral haemorrhage 
may present with the sudden occurrence of neurological dysfunction, including 
weakness, numbness, vision loss, diplopia, dysarthria, gait disorder, vertigo, aphasia, or 
disturbed level of consciousness. The rapid decline in neurological functions is typically 
more noticeable than with ischemic strokes. For example, if the haemorrhage is large 
enough, pressure effects on the whole brain and brainstem may lead to an obvious 
diminishing level of consciousness. In addition, a bleed that begins small (2 cm in 
diameter) may expand over the first few hours to become immense. This will cause a 
rapid deteriorating of symptoms, including a rapid reduction in the patient’s level of 
consciousness (Always et al., 2009). 
Stroke diagnosis involve several process including history taking, clinical exam, acute 
brain and cardiovascular imaging, and a number of basic laboratory tests are essential 
aids to the diagnosis of acute stroke. Acute brain imaging (CT or MM) are reliable 
methods of instant differentiation between ischemic stroke and intracerebral 
haemorrhage. After a large ischemic stroke involving the cortex or basal ganglia, early 
abnormalities on CT appear within 1-3 hours. Small and brainstem strokes may not be 
visualized for 12-24 hours on CT and may actually never be captured on CT. 
Clinical report assembled by clinician and radiologist that includes information such as 
suspected stroke localization as well as joint visualization of images is very important in 
understanding subtle abnormalities on brain imaging. MRI has many advantages 
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including a higher resolution, faster appearance of abnormalities and improved brain-
stern imaging for monitoring acute stroke patients, however it has limited access and is 
complicated in use. Moreover, perfusion-CT has appeared as a practical diagnosis tool 
for early ischemic attack and reliably differentiates reversible from irreversible ischemia. 
Lumbar puncture is necessary to rule out clinical suspicion of subarachnoid 
haemorrhage if the cranial CT or MRI is negative as in less than 10% of cases in the 
first 24 hours (Fisher, 2009). 
Treatment for acute stroke involves management, which was largely focused on 
rehabilitation and avoidance of adverse outcomes in the sub-acute setting. 
Administration rates of intravenous tissue plasminogen activator tPA were low despite 
the approval of IV tPA as an acute treatment for ischemic stroke in 1996. In the period 
from 1996 to 2002, only 0.6% to 8.5% of patients presenting with non-haemorrhagic 
stroke were being treated with IV tPA according to regional and nationwide studies in 
the United States and Canada. There are several possible reason for the low rate of IV 
tPA administration including the lack of painful symptoms, impaired communication that 
is often a symptom of stroke, the broad variety of possible symptoms, the frequent 
delays in activating emergency medical services, and the public's lack of knowledge of 
stroke symptoms. tPA has a limited treatment window of 3 hours and studies have 
demonstrated that only 17— 35% of stroke patients arrive within the time limit 
(Goldstein, 2011). 
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Blood Vessels. 
During the earliest stages of embryo development and in the absence of 
vascularization, nutrition is delivered through diffusion. When the embryo is developed 
into a highly vascular organism, it starts to depend on a functional, complex network of 
capillary plexuses and blood vessels. Vasculogenesis initiates vascular growth by 
forming primitive vessels. The second step of vascular growth is angiogenesis which 
causes the maturation and expansion of these vessels (Conway et al., 2001). 
 
Figure 5. Angioblasts in the embryo accumulate during the process of vasculogenesis, and 
expands and remodels in angiogenesis. Mural cells stabilize forming vessels by inhibiting 
endothelial proliferation and migration, and by triggering the production of extracellular matrix 
during vasularmyogenesis, Smooth muscle cells (SMC) enchase endothelial cells, providing 
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blood vessels with viscoelastic and vasomotor properties, essential to facilitate the changing 
requirements in tissue perfusion during arteriogenesis. CL, collagen; EL, elastin; Fib, fibrillin 
(Carmeliet, 2000). 
The largest blood vessels are arteries and veins, which have a thick, tough wall of 
connective tissue and many layers of smooth muscle cells. The wall is lined by a very 
thin single sheet of endothelial cells, the endothelium, separated from the surrounding 
outer layers by a basal lamina. The amounts of connective tissue and smooth muscle in 
the vessel wall vary according to the vessel's diameter and function, but the endothelial 
lining is always present. In the finest branches of the vascular tree the capillaries and 
sinusoids, the walls consist of endothelial cells only and a basal lamina, together with a 
few dispersed but functionally important pericytes. These are cells that belong to the 
connective tissue family, related to vascular smooth muscle cells that surround the 
small vessels. 
There are two cell types that compose all blood vessels; endothelial cells and mural 
cells. Mural cells associate with and surround the endothelial cell tube, whereas 
endothelial cells form the inner vessel wall. Mural cell are generally subdivided in 
vascular smooth muscle cells and pericytes, depending on their density, morphology, 
location, and expression of specific markers mural cell. Vascular smooth muscle cells 
are associated with arteries and veins and they construct multiple concentric layers 
surrounding these vessels. The wall of arteries and veins is lined by an extremely thin 
single layer of endothelial cells, the endothelium, isolated from the surrounding outer 
layers by a basal lamina. 
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Depending on the vessel's diameter and function, the amounts of connective tissue and 
smooth muscle in the vessel wall vary, however, the endothelial lining always exists. 
Arterioles, capillaries, and venules belong to the smallest diameter blood vessels which 
are associated with pericytes and share their basal membrane withthe endothelium. The 
walls of capillaries and sinusoids consist of endothelial cells and a basal lamina only 
together with few pericytes. Pericytes are either mono connected to the endothelial cell 
tube or form a single unconnected, cell layer enchasing it. They belong to connective-
tissue family, related to vascular smooth muscle cells that wrap themselves round the 
small vessels. The morphology and the degree by which pericyte enchase endothelium 
significantly differ between variable tissues (Gaengel et al., 2009, Alberts et al., 2002).
 
Figure 6. The scanning electron micrograph displays pericytes wrapping their processes around 
a small blood vessel in the mammary gland of a cat (Alberts et al., 2002). 
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Endothelial Cells. 
Endothelial cells line the entire vascular system, are versatile and have variety of 
functions and synthetic and metabolic properties, including the regulation of thrombosis 
and thrombolysis, platelet adherence, modulation of vascular tone and blood circulation, 
and regulation of immune and inflammatory responses by controlling leukocyte, 
monocyte and lymphocyte connections with the vessel wall. Abnormalities in endothelial 
structure and function may also result in development of diseases. They play an 
essential role in atherosclerosis, hemostatic dysfunction, and altered inflammatory and 
immune response. The structure and functional stability of endothelial cell are essential 
in maintenance of the vessel wall and circulatory function. The endothelial cell layer is 
semi-permeable and controls the passage of small and large molecules (Sumpio et al., 
2002). Endothelial cells play a critical role in the process of increased vascular leakage 
and thrombopathy during severe inflammation leading to shock. The surface of the 
endothelial cell alters from an anti- prothrombotic into a prothrombotic surface and the 
thrombosis resistance of the cardiovascular system is further reduced by the obstruction 
of endothelium-dependent relaxation. Endothelial cells can activate a different of 
cytokines and factors that change the haemostatic balance in a prothrombotic state. 
Endothelial cells can affect the activation, regulation and modulation of coagulation, in 
addition to the indirect effects of adhesion molecules, growth factor and cytokines. They 
regulate the activation of binding sites for anticoagulant and pro-coagulant factors on 
the cell surface. In normal conditions, they maintain blood flow by stimulating the activity 
of numerous anticoagulant pathways. The endothelium may become activated directly 
by pathogens or indirectly by inflammatory mediators during acute infections. There are 
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several pathways by which the endothelium is challenged subject to the type of 
pathogen. Changes in coagulation and fibrinolytic systems canbe initiated by direct 
activation by bacteria, viruses and other pathogens or indirect activation of the 
endothelium. Family of gram negative bacteria can activate endothelial cells by 
endotoxins. There are numbers of examples where viruses can invade endothelial cells 
including (para-) influenza, adenoviruses, herpes simplex virus (HSV), polio virus, 
echovirus, measles virus, mumps virus, cytomegalovirus (CMV), human T-cell 
leukaemia virus type-1 (HTLV-1) and human immunodeficiency virus (HIV). Infection of 
endothelial cells has been established for haemorrhagic fevers (HF) caused by Dengue, 
Marburg, Ebola, Hantaan and Lassa HF as well. HIV infection changes the coagulation 
system by impairment of heparin co-factor II (Stern et al., 1991) (Keller et al., 2003). 
Blood Brain Barrier: 
The blood–brain barrier (BBB) is a highly selective barrier that surrounds the central 
nervous system (CNS) including the spinal cord and protects the brain from the 
changing metabolite concentrations in blood. The BBB is necessary to provide an 
optimal chemical environment for cerebral function. It is formed by a complex cellular 
system of endothelial cells, astroglia, pericytes, perivascular macrophages, and a 
basement membrane consisting of type IV collagen; fibronectin and laminin. Astrocytes 
extend their end feet tightly to the cerebral endothelial cells (CEC), effecting and 
maintaining the barrier function of these cells. CEC are surrounded by the basal lamina 
along with pericytes and perivascular macrophages. Pericytes may affect the stability of 
the capillaries and protect the barrier function because of their tight contact with the 
endothelial cells. They also restrict transportation because of their ability to phagocytose 
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molecules that were able to cross the endothelial barrier (Vries et al., 1997, Hawkins et 
al., 2006). 
 
Figure 7. A representation of the BBB. It is formed by capillary endothelial cells, embedded in 
basal lamina and surrounded by astrocytic perivascular endfeet. The figure also shows 
pericytes and microglial cells. A number of transporters and receptors including EAAT1–3, 
excitatory amino acid transporters 1–3; GLUT1, glucose transporter 1; LAT1, L-system for large 
neutral amino acids; Pgp, P-glycoprotein are presented in a. Some endothelial cell receptors 
and transporters including 5-HT, 5-hydroxytryptamine (serotonin); ANG1, angiopoetin 1; bFGF, 
basic fibroblast growth factor; ET1, endothelin 1; GDNF, glial cell line-derived neurotrophic 
factor; LIF, leukaemia inhibitory factor; P2Y2, purinergic receptor; TGFbeta, transforming growth 
factor-beta; TIE2, endothelium-specific receptor tyrosine kinase 2 are shown in b (Abbott et al., 
2006). 
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BBB endothelial cells are characterized by the existence of a distinct phenotype, which 
is the presence of tight junctions TJs and a defined polarized transport systems. Apical 
intercellular junctional complex in polarized epithelium and endothelium consist of TJs. 
They have three major biological functions including blocking para-cellular diffusion of 
blood-borne polar substances, preventing the lateral diffusion of lipids and integral 
membrane proteins, therefore maintaining cell polarization and an intracellular signalling 
platform (Luissint et al., 2012). Tight junctions consist of two types of transmembrane 
proteins, and claudins. Occludin is a ∼60-kDa tetra-span membrane protein that forms 
two extracellular loops separated by a short cytosolic loop, and both amino- and 
carboxy-terminal domains are cytosolic. Phosphorylated occludin is located at tight 
junctions while non-phosphorylated occludin is localized to both the basolateral 
membrane and in cytoplasmic vesicles. It is suggested that occludin phosphorylation 
states and its localization and function within the tight junction is regulated by several 
kinase and phosphatases. Recruiting of occludin to tight junctions and regulating the 
para-cellular permeability barrier between cells are controlled by the extracellular 
domains of occludin. The claudin family consists of a minimum of 24 members falling 
within the range of 20–27 kDa and consist of a tetra-span transmembrane protein with 
two extracellular loops. Claudins function in localization of occludin to tight junctions. 
Claudins directly regulate the gate function of the tight junction, which controls the para-
cellular pathway for ion passage in-between cells in an epithelial layer. Most of the 
channels formed by claudin interactions permit the movement of cations, however the 
passage of anions has also been detected. Claudin ion selectivity can be influenced by 
changes in the type of claudin expressed, or single amino acid substitutions in claudins 
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(Schneeberger et al., 2004, Nelson et al., 2008). In leaky tight junctions, where a higher 
rate of ion flow, charge selectivity is most evident. The majority of leaky TJs 
demonstrate a preference for Na+ over Cl−, Charge selectivity is most relevant in leaky 
tight junctions where higher amounts of ions flow. Almost all leaky TJs show a 
preference for Na+ over Cl−, and between different epithelia and experimental cultured 
cell models, the permeability ratio within a range of 10 to 0.1. Epithelia with leaky TJs 
are found where movement of large amounts of isosmotic fluids is required, such as in 
the human gastrointestinal tract, which secretes and then reabsorbs around 10 L of fluid 
each day. In contrast, epithelia with tight junctions can sustain the high electrochemical 
gradients produced by active trans-cellular transport. This formation is used to result in 
either highly concentrated or diluted secretions, as in the distal nephron, which can 
produce urine with osmolarity several fold higher or lower than plasma (Itallie et al., 
2009). 
hCMEC/D3 cell line. 
In vivo studies have revealed a great deal of information regarding the distinctive 
properties of brain endothelium, however, whole animal experiments impose numbers 
of limitations. Therefore, new techniques to isolate and culture CNS-derived endothelial 
cells from various species have been developed (Weksler et al., 2005). One of these 
techniques includes manipulating endothelial cells with a combination of astrocyte-
conditioned medium and agents that elevate intracellular cAMP to establish a cell 
culture model of the blood brain barrier (Rubin et al., 1991). Cyclic AMP (cAMP) is a key 
second messenger that transfers information to a variety of many effector proteins 
within the cell (Ponimaskin et al., 2007). Epithelial tight junction permeability is affected 
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by cyclic AMP, which is established to be involved in mediating surface membrane 
phenomena in a variety of cell systems (Duffey et al., 1981). However, such model 
exhibited high electricalresistances, low permeability to small molecular weight 
compounds and functional expression of the most important drug transporters (Poller et 
al., 2008). Different rat brain endothelial (RBE) cell lines have been developed (RBE4, 
GP8/3.9, GPNT, RBEC1, TR-BBBs and rBCEC4 cell lines) as in vitro models of the 
BBB. Primary cultures of RBE cells were transduced with an immortalizing gene (SV40 
or polyoma virus large T-antigen or adenovirus E1A), either by transfection of plasmid 
DNA or by infection using retroviral vectors (Roux et al., 2005). Numbers of in-vitro 
models were developed in which EC are; either grown in astrocyte conditioned medium, 
or co-cultured with astrocytes or rat C6 glioma cells. The co-culture system can be 
either a non-contact co-culture with the glial cells seeded at the bottom of the well 
(Malina et al., 2009). 
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Figure 8. A representation of different in vitro cell-based blood–brain barrier (BBB) models. 
Monocultures of cerebral endothelial cells (CECs) are being replaced by co-culture or triple co-
culture systems. (A) CECs are seeded with astrocytes in a non-contact format. (B) CECs are 
seeded with astrocytes in a contact format. (C) CECs are seeded with pericytes in a non-contact 
format. (D) CECs are seeded with pericytes in a contact format. (E, F) Triple co-culture systems, 
in which more than one cell type is seeded with CECs (Bicker et al., 2014). 
One of these models was established using primary cultures of three main cell types of 
cerebral micro-vessels in order to develop and characterise a new syngeneic BBB 
model. Rat brain endothelial cells, pericytes and astrocytes were co-cultured to mimic 
the structural condition in vivo. It resulted in the elevated levels of tight junction proteins 
occludin, claudin-5 and ZO-1 with a typical arrangement at the cell borders. Electron 
microscopy provided further morphological evidence of the existence of inter-endothelial 
TJs (Nakagawa et al., 2009). 
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Non-cell based surrogate BBB model such as parallel artificial membrane permeability 
assay (PAMPA) was developed. It involves a non-biological artificial membrane and 
therefore only concentrates on the prediction of passive trans-cellular drug absorption. 
The system has the ability to identify compounds as either BBB permeable (BBB+) or 
non-permeable (BBB−) with adequate precision due to the modifications to the lipid 
composition of the artificial membranes (Mensch et al., 2010). 
The drawback of most of the in vitro models of the blood–brain barrier is the use of cells 
of non-human origin, which is not optimal for the estimation of brain permeability in 
humans. BB19 cells are derived from human brain endothelium and are immortalized 
with E6E7 genes of human papilloma virus. They in part sustain endothelial properties, 
which is demonstrated by tube formation in Matrigel™ ™ as substrate. They express 
Factor VIII-related antigen and von Willebrand's factor (Kusch-Poddar et al., 2005). 
Another human origin cell line is SV-HCEC, which isdevolved using human capillary and 
microvascular endothelial cells (HCEC) that were transfected with the plasmid pSVS-
neo coding for the SV4O large T antigen and the neomycin gene (Muruganandam et al., 
1997). The SV-HCEC line displays properties of the primary/ low passage brain 
capillary cells which include factor VIII-related antigen, uptake of acetylated low density 
lipoprotein, transferrin receptor mediated endocytosis, and elevated levels of the 
selective marker enzymes alkaline phosphatase and Υ–glutamy1 transpeptidase. 
However, immortalized brain endothelial cell lines including the human SV-HCEC; the 
mouse MBEC; the mouse TM-BBB4; the rat GPNT, the rat RBEC1; and the rat RBE4 
cell line appear to generate unsufficient restrictive para-cellular barrier properties that 
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would allow their effective use in trans-endothelial permeability screening (Gumbleton et 
al., 2001). 
One human BBB model that closely mimics the in vivo phenotype and is reproducible 
and easy to grow, is brain microvascular endothelial cell line hCMEC/D3. It was derived 
from human temporal lobe microvessels isolated from tissue removed during surgery for 
control of epilepsy. The primary isolate was enriched in CECs. In the first passage, cells 
were consecutively immortalized by lentiviral vector transduction with the catalytic 
subunit of human telomerase (hTERT) and SV40 large T antigen, following which CEC 
were selectively isolated by limited dilution cloning, and clones were extensively 
characterized for brain endothelial phenotype (Weksler et al., 2013). hCMEC/D3 
recapitulates many of the key characteristics of primary brain endothelial cells such as 
the expression of endothelial cell markers, transporters, and tight junctional proteins 
without the requirement of co-culturing with glial cells (Vu et al., 2009). As well as being 
a morphological barrier; BBB is also an active physical and metabolic barrier due to the 
expression of drug efflux transporters and drug-metabolizing enzymes. These 
transporters actively limit the entry of numerous endogenous compounds and 
xenobiotics into the brain. They involve ATP-binding cassette (ABC) efflux transporters, 
including P-glycoprotein (P-gp, ABCB1/MDR1), BCRP (ABCG2) and several MRPs 
(ABCCs) which are expressed at the luminal membrane of the endothelial cells forming 
cerebral microvessels. One of the major drug transporters at the BBB is P-gp, which is 
mainly expressed at the luminal membrane of brain endothelial cells in both humans 
and animals. All of these transporters where found to be expressed in the hCMEC/D3 
cell line (Dauchy et al., 2009). hCMEC/D3 cell line provided a reliable model of the 
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human BBB in numbers of researches including a study designed to investigate cellular 
and molecular mechanisms involved in endothelial changes induced by HTLV-1-
infected lymphocytes. hCMEC/D3 expresses a high restriction of permeability, and 
expresses chemokine receptors and up-regulated adhesion molecules in response to 
inflammatory cytokines which are properties of BBB. Therefore, hCMEC/D3 was used to 
study the mechanisms associated with retroviral-induced BBB disruption, both in terms 
of permeability to solutes as well as trans-endothelial migration of lymphocytes (Afonso 
et al., 2007). 
Angiogenesis. 
Angiogenesis, the formation of new blood vessels, is an important process involved in 
both normal physiological and numerous pathological process, such as tumor growth, 
metastasis, inflammation and ocular disease. Angiogenesis, or neovascularization, is 
the process of generating new blood vessels from a pre-existent vascular system. The 
principal cells involved are endothelial cells, which line all blood vessels and constitute 
virtually the entirety of capillaries (Auerbacha et al., 2003). Angiogenesis involves 
endothelial cell proliferation, selective breaking down of the basement membrane and 
the adjacent extracellular matrix, endothelial cell migration, and tube formation. The 
endothelial cells go through tissue-specific alterations to produce functionally distinct 
vessels, once new blood vessels have been formed. During embryogenesis, endothelial 
cell precursors (angioblasts) differentiate to form blood vessels. Angioblasts associate 
to form primitive vessels in a process called vasculogenesis (Hoeben et al., 2004). 
Vasculogenesis is required for the de novo formation of a vascular network in 
embryogenesis and growth. On the contrary, arteriogenesis refers to the remodelling of 
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pre-existing arterial vessels to form arteries. It is based on chemokine/growth factor-
induced growth processes and increases in diameter of vascular wall structures at 
increased stress that is induced by elevated pressure rates in arteries. During their 
lifespan, endothelial cells maintain their plasticity to detect and respond to angiogenesis 
stimuli. Generally, angiogenesis is firmly regulated by well-balanced activating and 
inhibiting signals including cytokines, hormones, endothelial cell migration, circulating 
progenitor cells and destabilization of the vessel wall, the basal lamina, and the 
interstitial matrix (Multhoff et al., 2014). Angiogenesis is also triggered by chemical 
signals from cancer cells. It plays an important role in the progression of cancer since 
the proliferation, as well as metastatic spread, of cancer cells relies on a sufficient 
supply of oxygen and nutrients and the removal of waste products. In contrast, in the 
absence of vascular support, tumours may become necrotic or even apoptotic. There 
are numbers of different proteins that have been identified as angiogenic activators and 
inhibitors and the rate in which angiogenic factors are expressed reflects the 
aggressiveness of cancer cells. Thus, the use of Angiogenic inhibitors in cancer therapy 
could reduce both morbidity and mortality from carcinomas (Nishida et al., 2006). Anti-
angiogenic therapy has the potential to overcome two major problems facing the non-
surgical treatment of malignant solid tumours. First is the obstructionof drug delivery at 
effective concentrations to all cancer cells due to physiological barriers within tumours. 
Second, genetic and epigenetic mechanisms causing drug resistance reduces the 
effectiveness of available therapies (JAIN et al., 2001). Anti-angiogenic therapy targets 
vascular growth within tumours to suppress tumour growth and metastasis. Most 
present anti-cancer chemotherapeutic agents administered clinically indiscriminately 
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target all rapidly dividing cells. Therefore, they can cause acute negative effects such as 
immunosuppression, abdominal problems and hair loss. On the contrary, anti-
angiogenic reagents have less adverse effects because, except in the uterine 
endometrium during the menstrual cycle, neoangiogenesis (formation of blood vessel in 
tumour tissue) rarely occurs in healthy adults (Kubota, 2012). In ischemic diseases, in 
contrast, deprivation of oxygen and nutrients causes a serious threat for tissue survival. 
In response to tissue ischemia, angiogenic growth factors are upregulated, and 
circulating cellular elements are mobilized to enable new blood vessels formation. 
Therefore, it is an important therapeutic option to induce vascular growth after critical 
ischemia. Growth factors, which mostly act on endothelial cells to stimulate endothelial 
cell proliferation, migration, and tube formation, are potential therapeutic genes for 
angiogenesis or arteriogenesis enhancement. At the same time, growth factors cause 
endothelial cells to become less sensitive for apoptosis induction. Fibroblast growth 
factor (FGF) families and Vascular endothelial growth factor (VEGF) were among the 
first growth factors to be identified (Losordo et al., 2004). However, VEGF-induced 
angiogenic vessels are haemorrhagic, aggravating inflammatory responses in the 
recovering area surrounding an ischemic event. The penumbra is intensely resilient and 
is a site of extreme remodelling and active angiogenesis (Jawahar Mehta, 2013). 
Angiogenesis plays an important role as a recovering mechanism in response to 
ischemia in numerous non-CNS tissues. For instance, drugs that enhanced 
angiogenesis can sometimes reduce injury in myocardial infarction and limb ischemia 
because these disorders can activate endogenous angiogenesis in each organ. 
However, the responses and regulatory mechanisms in the brain that trigger 
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angiogenesis might be more complex. In autopsy studies it was found that brain 
ischemia activates angiogenesis through Hypoxia-inducible factor (HIF) pathways. 
Despite the fact that increasing blood flow and reducing the size of the infraction by 
forming new vascular networks to improve neurological recovery through pro-
angiogenic therapy, the information about such therapy remains random and indirect. In 
a study, it was demonstrated that the number of new blood vessels in areas surrounding 
stroke site associated with longer survival in stroke patients, which suggests that active 
angiogenesis might beneficial for ischemic brain. It is hypothesized that in transit 
ischemic attacks, signals for angiogenesis should be activated, which could explain why 
patients with such attacks show less severe brain damage that those without such 
episodes (Navaratna et al., 2009). 
Matrigel™ : 
Matrigel™ Basement Membrane Matrix, is the trade name for a cell culture medium 
comprised gelatinous protein mixture secreted by Engelbreth-Holm-Swarm (EHS) 
mouse sarcoma cells. It has numerous uses including supporting of multicellular three-
dimensional growth and altered cell morphology, proliferation, differentiation of cancer 
cell culture. In addition, it increases tumourigenicity for the establishment of xenograft 
tumour models in vivo when used as an injection medium for cancer cells (Price et al., 
2012). The Matrigel™ plug assay is used to measure angiogenesis in vivo, it offers a 
versatile base to study the formation new microvessel as well as the effects of pro- and 
anti-angiogenic factors. It forms a support for the proliferationof vascular structures by 
self-assembles from a liquid at 4° to a semi-solid at 37°C (Bartoli et al., 2012). 
Matrigel™ provides a three-dimensional (3D) cell culture models which allow studies 
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into biological functions in a condition that is similar to in vivo setting and therefore 
provides a more physiological context. Three-dimensional model systems are presently 
being used in order to examine the signals that modulate normal processes of tissues 
and how they may be disturbed in pathological conditions such as cancer. Cell culture 
studies are normally conducted on synthetic substances such as glass or plastic that 
restrict cells to adhere to artificially flat and rigid surfaces. The benefit of using these 
two-dimensional (2D) in vitro cell culture systems is their ability to provide convenient 
and rapid methods of biochemical analysis. However, unlike 3D systems, they are 
inefficient in signals found in tissue microenvironments in vivo; thus, limiting the use of 
these studies for tissue-specific functions and structural signals (Sodunke et al., 2007). 
 
Table 1. Examples of how Matrigel™ promotes differentiation in different cell types. ª Denotes 
activity with both primary cells and cell lines (Kleinman, 2005). 
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Matrigel™ is usually stored as a frozen solution for long term use, and thawed overnight 
at 4 °C before application. It solidifies at 24–37 °C in 30 min and it does not re-dissolve 
readily upon cooling. Cells are either seeded on top of the gelled material, or mixed with 
the matrix before gelling. When exposed to Matrigel™ , many cell lines and primary 
cells, differentiate rather than proliferate (Kleinman et al., 2005). Its main constituent is 
laminin, followed by collagen IV, heparansulfate proteoglycans, entactin, and nidogen. It 
also contains growth factors such as transforming growth factor-beta, fibroblast growth 
factor, tissue plasminogen activator, and others. It can be adjusted to remain in a liquid 
form by adding different amounts of Matrigel™ to pure cell culture medium to recreate 
an environment as close as possible to the in vivo one (Lazzaroni et al., 1999). 
Matrigel™ contains many essential components of the extracellular matrix such as 
collagen, laminin, entactin, and other important growth factors. Cultured epithelial cells 
respond to such appropriate matrix proteins which are similar to the components of 
matrix found in the tissue of origin. In a study, Matrigel™ was utilized using mammary 
gland to provide an ideal model for understanding connection between normal tissue 
function and architecture. Acinus is 3D structure formed by mammary epithelial cells 
that exist in 3D space. In acinus, a single continuous layer of epithelial cells secrete milk 
into a central lumen. In vivo, this 3D architecture is surrounded by a layer of 
myoepithelial cells and extracellular matrix proteins that provide structural support and 
functional information. This overall structure and function can be replicated in vitro by 
culturing mammary epithelial cells completely enchased by Matrigel™ . Growing 
epithelial cells in 3D cultures provides an environment where cyst-like spheroids with a 
hollow lumen can be formed and cells build their own basement membrane, have a firm 
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control over proliferation, and form apicobasal polarity.When a single human 
immortalized mammary epithelial cell (MCF-10A) is seeded in or on top of a layer of 
Matrigel™ (approximately 1 mm thick) and surrounded by additional Matrigel™ , cells 
undergo a morphogenetic pathway that causes the formation of acini-like structures 
highly similar to normal epithelial architecture (Sodunke et al., 2007). 
Cell Migration. 
The in vitro cell migration assay is a simple and cost-effective method to study cell 
migration in vitro. Cell monolayers act in a response in any disruption of cell-cell 
contacts, due to a wound or scratch, by increasing concentration of growth factors at the 
wound margin and healing the wound through a combination of proliferation and 
migration. These procedures represent the behaviour of individual cells as well as the 
properties of the cell sheet as a surrogate tissue. In order to conduct a cell migration 
assay, a pipette tip or syringe needle is used to introduce a wound in a confluent cell 
monolayer grown on an individual coverslip or in a multi well plate. The process of cell 
migration can be then observed over a period of 3–24 hrs. Cells migrate in a typical way 
where cells on the edge of the newly created gap polarize to the wound, start 
protrusion, and migrate until new cell–cell contacts are established again. The process 
of cell migration can be recorded by capture of images at the beginning and regular 
intervals during cell migration to close the scratch, and comparison of the images to 
determine the rate of cell migration (Yarrow et al., 2004, Liang et al., 2007). Cell 
migration is involved in several normal and pathological processes, including embryonic 
growth, protection against infections, wound healing, and tumour cell metastasis. It is 
commonly known that dynamic reorganization of the actin cytoskeleton, directing 
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protrusion at the front of the cell and retraction at the back are the stimulants of cell 
migration. Moreover, cellmigration efficiency relies on synchronised changes in other 
cellular activities including provide new membrane components through directed 
secretion, regulating adhesion by turnover of cell–matrix interactions, and providing 
autocrine/ paracrine signals by alterations in gene transcription (Hall et al., 1999). Cell 
migration is one of many biological processes that are regulated by growth factors, 
cytokines and cellular matrix molecules. Paxillin is found to be involved in a number of 
biological functions including cell adhesion, cell migration and neurite outgrowth. It is a 
68-kDa focal adhesion-associated that contains five leucine-rich regions, termed LD 
motifs, near the N-terminus, and four LIM domains in the C-terminus. Spread 
throughout paxillin are many serine/threonine and tyrosine phosphorylation sites. 
Phosphorylation of paxillin on these sites in response to extracellular stimuli leads to 
recruitment of a number of signaling molecules, therefore regulates focal adhesion 
dynamics and cell migration (Huang et al., 2008). 
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Figure 9. Signalling pathways for cell migration regulated Erk. Growth factors, such as PDGF, 
EGF and FGF, activate Ras-Raf-MEK1/2 which in turn activate Erk.Activated Erk mediates 
membrane protrusions and focal adhesion turnover via phosphorylating MLCK and stimulates 
focal adhesion disassembly via phosphorylating and activating calpain. Phosphorylation of FAK 
and paxillin by Erk may control focal adhesion dynamics, possibly by affecting the paxillin-FAK 
interaction. Orange lines indicate hypothetical pathways (Huang et al., 2004). 
Apoptosis: 
Apoptosis or programmed cell death is the most common form of physiologic cell death 
in multicellular forms. It is highly cell-specific and could be induced in damaged cells, 
where damage is beyond repair (Rastogi et al., 2009). It has a number of characters 
including energy-dependent biochemical mechanisms and distinct morphological 
properties. Apoptosis is a key part in several biological processes such as normal cell 
58 | P a g e  
 
turnover, proper development and functioning of the defence system, hormone-
dependent atrophy, embryonic development and cell death caused by chemicals. Any 
abnormalities in apoptosis could affect many human conditions including 
neurodegenerative diseases, ischemic damage, autoimmune disorders and various 
types of cancer (Elmore, 2007). There are two major pathways in which apoptosis is 
initiated. The extrinsic pathway is mediated by a sub-group of Tumor Necrosis Factor 
receptors (TNFR) superfamily that includes TNFR, Fas and TRAIL (Portt et al., 2011). 
Activation of theses death receptors activate death-inducing signaling complex (DISC) 
formation and caspase 8 activation, which in turn activates caspase 3.The second major 
pathway is the intrinsic pathway which can be activated by proteolysis of BID to t-BID by 
caspase 8 and interaction of t-BID with BAX in the mitochondria (Chiong et al., 2011). 
This pathway is consequently controlled by members of the Bcl-2 family. Regardless of 
different modes of initiation between the extrinsic and intrinsic pathways, they bothresult 
in the same outcome; which is the activation of a cascade of proteolytic enzymes, 
members of the caspase family (Sprick et al., 2004). 
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Figure 10. A representation of the two major apoptotic pathways; the extrinsic and the intrinsic 
pathway. The death-receptor activate the extrinsic pathway that acts through caspase 8 or 
mitochondrial intrinsic pathway. The intrinsic pathway activates caspase-activating complex 
(that includes cytochrome c and apoptosis-activating factor 1 APAF1) that acts on caspase 9 
which in turn activate caspase 3. Both pathways are regulated by BCL2 and inhibitor of 
apoptosis IAP protein families. BCL2 proteins are believed to regulate the mitochondrial 
permeability promoting BID and cytochrome c release (Andersen et al., 2005). 
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Aims. 
The aims of this study were: 
 To study the protective effects of citicoline on endothelial cell apoptosis. 
 To investigate the key signalling mechanism through which citicoline modulates 
apoptosis. 
 To determine the angiogenic effect of citicoline using in vitro angiogenesis 
assays. 
 To investigate the key signalling mechanism through which citicoline modulates 
angiogenesis. 
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Chapter 2 Materials & 
Methods 
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Materials and Methods. 
 
Materials   
 
 Chromatography paper (WhamanSchleicher&Scuell international Ltd, England). 
 Coverslips (Scientific laboratory supplier Ltd, UK). 
 Cryovials (Nunc Corporation, Roskilde, Denmark). 
 Eppendorf tube 1.5 ml and 500 µl (Nunc)  
 Nitrocellulose membrane (Schleicher&Schuell). 
 Pipettes 0.5-10,5-50,50-200,100- 1000 µL (Sicentificlabarotory supplies Ltd (SLS)). 
 Sterile bijous (SLS)   
 Sterile plates 6-well, 24-well and 48-well (Nunc, Denmark) 
 Sterile universal containers (SLS)  
 Superfrost slides (76x26) mm (Thermo Scientific, Germany) 
 Tips 
 Tissue culture flasks (T-25) (Scientific Laboratory Supplier, UK)  
Equipment.   
 
 Autoclave (Lab Impex Research, UK)  
 Autovortex mixer SA1 (Stuart Scientific Co, UK) 
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 Axivoert fluorescence microscope (Zeiss, Oberkochen, Germany) 
 Balancer (Sartorius analytic). 
 BD FACSCalibur™ Flow Cytometer (BD Biosciences, UK). 
 Centrifuge (Mik20). 
 CO2 incubator (Lab Impex Research, UK)  
 Elecrophoresis unit mini-Protean® 3 (Bio Rad, USA). 
 Freezer -80°C (Juan Quality System, UK). 
 G-box (Syngene,UK). 
 Ice maker (Borolab Ltd, UK). 
 Image J software analyzer (Free on line software). 
 Laboratory fridge (Scientific laboratory Supplies, UK). 
 Laboratory pH/ temperature meter (Model AGB-75, UK). 
 Laminar flow hood tissue culture grade (Walker safety cabinet Ltd, UK). 
 Liquid nitrogen (BOC CryospeedThermolyne)  
 Magent stirrer hot plate (Stuart Scientific CO., UK)  
 Microscope (Nikon TMS)  
 Modular incubator chamber (Billups-rothenberginc., USA). 
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 NanoDrop (Thermo Scientific, USA).  
 Nikon camera (Nikon coolpix 4500)  
 Power supply PS-251-2 (Sigma-Aldrich)  
 Rotating shaker (Grant-bio PS0-300)  
 Spectrophotometer (Pharmaxia Biotech). 
 TC10™ Automated Cell Counter (Bio-Rad, USA)  
 Trans-blot SD semi-dry transfer (Bio-Rad, USA) 
 Ultra low -80 freezer (Nuaire, USA)  
 Water-bath (Grant instrument Ltd., UK)   
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Required buffers   
 
 Blocking buffer: 1% BSA in TBS –Tween. TBS-Tween must be stored in the refrigerator 
at PH7.4 or 3 % of non-fat dry milk in PBS-Tween.  
 Electrode buffer: 12.02 g Tris-base, 4g SDS, 57.68g glycine made up with 2 L of dH2O. 
 Milk (required for the secondary antibodies): 5% milk in TBS-Tween with PH adjusted to 
7.4. Must be stored in the refrigerator for 7 days. 
 Sample buffer (PH 6.8): 1.51 g of Tris-base, 20 ml glycerol mixed with 20 ml of d H2O. 
Then add 4g of SDS, 3.6 ml of mercaptoethanol and 0.004 g bromophenol blue made 
up to 100 ml with d H2O. 
 Separating buffer (PH 8.8): 36.3 g Tris-base, 0.8 g of SDS dissolved in 250 ml of d 
H2O.  
 Stacking buffer (PH 6.8): 15 g Tris-base, 1g SDS dissolved in 250 dH2O.  
 Towbin buffer: 1.51 g Tris-base,7.2 g glycine, 0.167 g SDS, 75 ml methanol. This 
combination was made up to 500 ml with dH2O.    
 Tris buffered saline and tween-20 (TBS-Tween PH 7.4): 2.422 g Tris-base, 16.36 g 
NaCl and 2 ml of tween 20 mixed up to 2 L with dH2O. 
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Cell culture medium.  
Endothelial cell basal medium-2 (EBM-2) supplemented with 2% FBS, Hydrocortisone, 
recombinant human Fibroblast Growth Factor B (rhFGF-B), recombinant human 
Vascular Endothelial Growth Factor (rhVEGF), Recombinant long Receptor Insulin-like 
Growth Factor-1(R3 IGF-1), Ascorbic Acid, recombinant human Epidermal Growth 
Factor (rhEGF), Gentamicin sulphate Amphotericin-B (GA-100).  
 
Methods.   
 
Cell culture and sub-culture.   
Human Cerebrovascular Microvessel endothelial cell line hCMEC/D3 was grown in 
EBM-2 medium supplemented with growth factors and hydrocortisone. Cells were 
seeded into T25 flasks pre-coated Poly-L-lysine solution 0.1 % and maintained in a 
humidified 5% CO2 atmosphere at 37 °C. Every three days reaching the confluence, the 
cells were detached under the enzymatic activity of the trypsin. Briefly, medium was 
discarded and the cells were washed with approximately 5-10 ml of PBS without Ca++, 
Mg++. Then, 1 ml of trypsin (2X) was added and incubated for 3 min in order to detach 
confluent cells from the flasks. Following that, the action of the trypsin was blocked by 
adding an equal amount of fresh medium. Then, the cells in the suspension were 
collected in a universal tube and centrifuged at 1300 rpm for 5 minutes. The 
supernatant was then discarded and the cell pellet was re-suspended with fresh 
complete medium. The cells were seeded into new pre-coated flasks. Throughout the 
study, the cells used in all assay were between passages 28 and 38. 
 
67 | P a g e  
 
Preparation of freezing medium.   
Freezing medium was prepared containing 10% DMSO in FBS. Briefly 1 ml of DMSO in 
9 ml of cold FBS was mixed and kept at -20°C until used.  Fresh freezing medium was 
prepared or defrosted shortly before use.  
Freezing and thawing of cells.   
Cells taken from the flask were centrifuged 1300 rpm for 5 minutes, the supernatant 
was removed and the cells re-suspended in 250 µl of complete medium with the 
addition of 750 µl of 10% (v/v) Dimethyl Sulphoxide (DMSO). One ml of the medium 
containing approximately 3.5 x 10⁵  of cells was kept in 1.5 cryovials labelled with cell 
passage, number and date. Cryovials containing cells were kept at -20 °C (30 min). The 
cryovials were transferred into a -80ºC freezer overnight. After at least 24 hours, 
cryovials were transferred to liquid nitrogen and the location was recorded. When 
required, cryovials containing the cells were taken from liquid nitrogen, and wiped with 
alcohol. The pressure inside the vial was released inside a Laminar flow hood and the 
frozen cells were defrosted at 37°C water path. Once defrosted, the cells were 
transferred immediately to pre-warmed complete medium. The cells suspension was 
centrifuged at 1300 rpm for 5 min, the supernatant discarded and the cell pellet 
suspended in 5 ml fresh medium. Cells were washed three times to removes traces of 
DMSO and seeded into a T25 or T75 cell culture flask at the required density. 
Cell counting: 
Cell counting was made usingTC10™ automated cell counter. From sub-culturing of 
hCMEC/D3, 10 μl of cell suspension was added into an eppendorf tube containing 10 µl 
of trypan blue dye. The sample was then loaded onto a dual-chamber slide. The slide 
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was inserted into the TC10 cell counter and the counting automatically began. Finally, 
total cell count was obtained from the screen. 
 
Angiogenesis assays. 
Cell proliferation assay. 
hCMEC/D3 cells were seeded at a concentration of 8 × 10⁴  cells/ml in 1 ml of complete 
basal medium in each well of 6-well plates. After 24 h incubation, the medium was 
replaced with SPM containing 1% FBS with different concentrations of citicoline (1 μM, 
5 μM and 10 μM ). After 72 hours incubation, cells were washed with PBS and detached 
with trypsin. Then, the cells were counted in a TC10™ automated cell counter at least 
three times for each well. In this experiment, cells were treated in triplicate for each 
experimental condition.  
Cell migration (Wound Healing). 
 
Cells were seeded at a concentration of 2 × 10⁵  cells/ml in a 500 µl of complete basal 
medium in each well of a poly l lysine pre-coated 24-well plates. After 24 hours 
incubation at 37 °C in 5% CO2, the medium was replaced with SPM containing 1% 
FBS. Each well of 24-well plates was washed with PBS 3 times and wound was made 
using a sterile pipette tip. The wells then were washed carefully with PBS to remove any 
floating cells and medium with SPM containing 1% FBS was added. Different 
concentrations of citicoline (1 μM, 5 μM and 10 μM) were added and the cells were 
incubated in hypoxia (1% O2) for 24 hours. 50 µl of 4% paraformaldehyde was added 
into each well to fix the cells for 5 min. The medium was then removed and the wells 
were washed with PBS. 100 µl of 100% ethanol was added to the cells and left for 5 
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min. Then the ethanol was removed and the wells were left to dry before staining the 
cells with methylene blue for 5 min. The stain was removed and the wells were washed 
with distil water. Finally the cells were examined under the microscope and pictures of 
the results were taken. In this experiment, cells were treated in triplicate for each 
experimental condition and pictures of five areas of each well were taken. The picture 
analysis was performed using image-J.  
Tube like-structure formation in Matrigel™. 
 
hCMEC/D3 cells (1.5×10⁶  cells/ml) were mixed with equal volume of growth factor-
reduced Matrigel™ ™ containing citicoline (10 μM) with or without ErbB-2 inhibitor, 
FGF-2 (25 ng/ml). Any material in the contact with the gel was cold to avoid the gel 
polymerization. In a 48-well plate, a total amount of 35 μl of this mixture was placed in a 
tear-like drop in the middle of the well and left to polymerize for 1 h incubation. Then, 
500 μl of complete medium was added into each well. After 24 h incubation, 4% of PFA 
was added to fix the endothelial tube-like structures in the gel. Under optical 
microscope, closed areas surrounded by endothelial tube like-structures were counted 
in 5 areas from each well. 
Hypoxia studies.   
Here to study the protective effect of citicoline on endothelial cells in hypoxia. Glass 
coverslips were bathed in 100% ethanol for 10-20 min and left to air dry in a sterile 
environment. The coverslips were put in a 24-well plate and pre-coated with 500 μl of 
0.1 % poly-L-lysine solution. After 10 min incubation, the coverslips were washed with 
PBS and the cells were grown in complete medium at a cell concentration of 5×10⁴  
cells/ml. After 24 hours incubation, the medium was removed and replaced with SPM 
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and incubated for 24 hours in normoxia. Different concentrations of citicoline was added 
to each well (1μM, 5μM, 10μM) in addition to untreated cells, then the cells were 
incubated in hypoxia (1% O2) for 24 h. One hour before the termination of the 
experiment, propidium iodide (PI; 10 μg/ ml) was added in each well as an indicator of 
DNA damage without removing the medium. After 1 h incubation, the cells were washed 
with PBS. After 30 min, the cells were washed three times with PBS and one drop of 
Vectashield mounting medium with DAPI reagent was added on frosted glass slides. An 
average of three fields at x40 of magnification was photographed per coverslip by using 
Axivoert fluorescence microscope. A 24-well plate was run with similar experimental 
condition in normoxia. In this experiment, triplicate wells were carried out for each 
experimental condition with the control, the untreated cells. 
Protein extraction and estimation. 
  
hCMEC/D3 cells (3.8 × 10⁵  cells/ml; 2 ml) were seeded in complete medium in 6- well 
plate. After 48 h incubation, the medium was replaced with SPM containing 1% FBS. 
Different concentrations of citicoline was added to each well (1μM, 5μM, 10μM) in 
addition to untreated cells, then the cells were incubated in hypoxia (1% O2) for 24 
hours. Then the cells were washed with 1 ml of PBS and gently lysed on ice in 50 μl of 
ice-cold homogenized lysis buffer (pH 7.2). The cells were scraped, the cell lysate 
proteins collected and transferred into 0.5 ml micro-centrifuge tube. The protein 
concentration was determined using the BioRad protein assay. Briefly, BSA was used at 
1mg/ml (1 μg/ μl) as a standard protein, 10 μl of protein lysate was added and 
completed with 90 μl of dH2O in a bijou. After that, 2 ml of BioRad protein assay was 
added in each bijou. The O.D of each sample was measured with spectrophotometer at 
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590 nm. The data outlining the reading of each protein samples and the standard curve 
required for protein estimation are shown below.   
BSA Standard 
( μg) 
BSA volume 
added (1μg/ µl) 
Volume of dH2O 
(µl) 
Volume of  
diluted Biorad 
(ml) 
0 0 100 2 
10 10 90 2 
20 20 80 2 
40 40 60 2 
Table 2. The volume of BSA, dH2O and Bio-Rad required to establish the standard curve. 
 
Figure 11. Standard curve for protein amount estimation in μg. 
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Western blotting.   
The acrylamide gel was prepared by mixing 3.3 ml of 40% bis-acrylamide with 4.2 ml 
distilled water and 2.5 ml separating buffer in a universal tube. 100 µl of 10% 
ammonium persulphate (APS) solution was added followed by 10 µl TEMED solutions. 
Few drops of isopropanol were added on top of the gel and the gel left to polymerise for 
20 minutes. Isopropanol was removed after 15 minutes and rinsed with plenty of dH2O, 
for one minute.  As much as possible, dH2O was removed by filter paper and then the 
stacking solution was prepared in a second universal tube, by combining 1.45 ml of 
40% bis-acrylamide with 6.1 ml dH2O, and 2.5 ml stacking buffer. As before, 100 µl 
APS was added followed by 10 µl TEMED solution and the gel left to polymerise for a 
minimum of 20 minutes.  Slowly the combs, clamps, and gaskets were then removed 
taking care not to damage the wells and the gel plates inserted into the electrophoresis 
chamber. The chamber was subsequently filled with electrode buffer (25 mMtris, 192 
mM glycine, 0.1% SDS, pH 8.3). A total of 500 ml electrode buffer was used to fill the 
tank, in the space between the two sets of glass plates. Take samples, sample buffers 
and molecular weight marker out of freezer and warm in room temperature. The protein 
concentration of each sample was determined by Bio-Rad protein assay to insure equal 
protein loading/well. Equal measures of protein sample and sample buffer were mixed 
in eppendorf tube, the tubes were placed in boiling water for 15 minutes. Molecular 
weight marker 5 µl and the protein samples were gently loaded. Samples containing 15 
μg protein (up to 20 µl solution), along with pre-stained molecular weight markers, were 
separated by SDS- PAGE (12%) for~45 minutes at 60 V (when samples were in 
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stacking gel) and switched to 200 V for separation until the dye, bromophenol blue, 
reached the bottom of the separation gel.   
Material Volume 
ddH2O 4.2 ml 
40% Acrylamide  3.3 ml 
Separating Solution* 2.5 ml  
10% APS 100 µl 
TEMED  10 µl 
 Total volume 10.11ml 
* Preparation method in page 66. 
Table 3. Preparation of separating gel 
Material Volume 
ddH2O 6.1 ml 
40% Acrylamide  1.4 ml 
Stacking Solution* 2.5 ml  
10% APS 100 µl 
TEMED  10 µl 
 Total volume 10.11ml 
* Preparation method in page 66. 
Table 4. Preparation of stacking gel.  
Blotting. 
Two nitrocellulose membranes (NCM) and 12 pieces of chromatography paper were 
soaking for 2 minutes in towbin buffer. Stacking gels were removed from the separation 
74 | P a g e  
 
gels and discarded. The gels were sandwiched separately. The sandwich was 
assembled in an electro-blotter for each gel as follows: Three pieces of blotting paper 
/NCM/gel/3 pieces of blotting paper. Any bubbles within the sandwiches were removed 
by rolling a clean 5 ml tip over the sandwich.  Proteins were transferred to the 
membrane at 45 mA per gel for one hour.   
Blocking.   
 
Membranes were blocked with 1% BSA incubation for 1 hour at room temperature on 
rotating shaker. BSA was discarded and membranes were incubated separately in 10 
ml of primary antibody solution (1:1000) dilution (rabbit polyclonal anti- ERK 1/2, mouse 
monoclonal antibodies to pERK1/2, rabbit polyclonal anti-Caspase 3 antibody,rabbit 
polyclonal anti-Caspase 3 active antibody, anti-Cleaved PARP antibody rabbit 
polyclonal,anti-PARP antibody rabbit polyclonal, anti-ErbB 2 (phospho Y1221)rabbit 
polyclonal antibody, anti-phospho-Histone H2B (Ser14) rabbit polyclonal antibody,anti-
Histone H2B rabbit polyclonal antibody ) at 4°C. After overnight incubation on a rotating 
shaker, primary antibody solutions were transferred into labelled universal tubes and 
sodium azide was added to a final concentration of 0.02% (w/v) to prevent microbial 
contamination, the primary antibodies then should be kept at 4°C and can be used for 
up to a week. The membranes were washed five times in tris buffered saline and tween-
20 (TBS-tween) for 10 minutes each at room temperature on rotating shaker. 
Membranes were incubated for 1 hour at room temperature in 10 ml of mouse anti- 
rabbit or rabbit anti-mouse horseradish peroxidase-conjugated secondary antibody 
diluted in TBS-tween containing 5% (w/v) skim milk (1:1000). After incubation, 
75 | P a g e  
 
secondary antibody solutions were discarded and membranes were washed five times 
in TBS-tween for 10 minutes each at room temperature on a rotating shaker.  
Imaging and data analysis.   
 
In a dark room, membranes were immersed in enhanced chemiluminescence (ECL) 
solution. Chemiluminescent is a chemical reaction that generates energy in the form of 
light and fades over time. To prepare the ECL solution, 1 ml of solution-A was added to 
1 ml of solution-B and kept in the dark room for five minutes. Once the ECL solution 
was prepared it was then poured on to the membranes for one minute and left in the 
dark room excess reagent was drained off and membranes were quickly wrapped in 
cellophane films and kept in a box. After the dark room, the membranes in box were 
taken to the G-Box and were measured as a chemiluminescent samples. The intensities 
of bands on the membranes were quantified by image analysis software. Day to day 
variations in luminescence could arise due to protein degradation or experimental 
errors. Therefore, loading controls are essential for proper interpretation of western 
blots and can be used to normalize the levels of protein detected by confirming that 
protein loading is the same across the gel. The expression levels of the loading control 
should not vary between the different sample lanes. The results were semi- quantitative 
and compared to the control.   
Flow Cytometry. 
 
The Annexin V-FITC Apoptosis Detection kit was used to detect apoptotic cells by flow 
cytometry. The annexins are a group of homologous proteins which bind phospholipids 
in the presence of calcium. Annexin V-FITC is a fluorescent probe which binds to 
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phosphatidylserine in the presence of calcium. The procedure consists of the binding of 
annexinV-FITCto phosphatidylserine in the membrane of cells, which are starting the 
apoptotic process, and the binding of propidium iodide to the cellular DNA in cells where 
the cell membrane has been completely compromised. hCMEC/D3 cells (3.8 × 10⁵  
cells/ml) were seeded in complete medium in 3×6- well plates. After 48 h incubation, the 
medium was replaced with SPM containing 1% FBS. Different concentrations of 
citicoline was added to each well (1μM, 5μM, 10μM) in addition to untreated cells, 6-well 
plate was incubated in hypoxia (1% O2) for 24 hours while the others were incubated in 
a 5% CO2 incubator. The Annexin V-FITC Apoptosis Detection kit components were 
allowed to reach room temperature before use. Binding buffer was prepared by diluting 
1 ml of the 10 × binding buffer with 9 ml of deionized water. Apoptosis was induced in 
one well with the addition of 1 mg/ml staurosporine at the same time a control of non-
induced hCMEC/D3 cells was established and both (treated and untreated cells) were 
incubated for 1 hour in a 37 °C, 5% CO2 incubator. All hCMEC/D3 cells in the 
experiment were re-suspended in 1× Binding Buffer.500 ml of the all cell suspensions 
were added to labelled plastic 12 × 75 mm test tubes. 5 ml of Annexin V FITC 
Conjugate was added and 10 ml of Propidium Iodide Solution to each cell suspension. 
The tubes were then incubated in the dark at room temperature for 10 min. The 
fluorescence of the cells was measured immediately with a flow cytometer. Cells, which 
are early in the apoptotic process, will stain with the Annexin V FITC Conjugate alone. 
Live cells will show no staining by either the Propidium Iodide Solution or Annexin V 
FITC Conjugate. Necrotic cells will be stained by both the Propidium Iodide Solution and 
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Annexin V FITC Conjugate. In this experiment, triplicate wells were carried out for each 
experimental condition. 
Immunofluorescence. 
 
Glass coverslips were bathed in 100% ethanol for 10-20 min and left to air dry in a 
sterile environment. The coverslips were put in a 2×24-well plate and pre-coated with 
500 μl of 0.1 % poly-L-lysine solution. After 10 min incubation, the coverslips were 
washed with PBS and the cells were grown in complete medium at a cell concentration 
of 5×10⁴ cells/ml. After 24 hours incubation, the medium was removed and replaced 
with SPM and incubated for 24 hours in normoxia. Different concentrations of citicoline 
was added to each well (1μM, 5μM, 10μM) in addition to untreated cells, one 24-well 
plate was then incubated in hypoxia (1% O2) for 24 h while the other was incubated in 
normoxia for the same period of time. The medium was removed carefully and the cells 
were washed with PBS. Cells were fixed in 4% Paraformaldehyde (PFA) for 20 minutes 
at room temperature, then rinsed 3x with PBS. The samples were blocked in 10% goat 
serum for 30 minutes at room temperature. The samples then were incubated with 
primary antibody 1:100 diluted in 10% goat serum (rabbit polyclonal anti-Caspase 3 
active antibody and anti-phospho-Histone H2B (Ser14) rabbit polyclonal antibody) for 
1hour at room temperature. After the 1 hour incubation the coverslips were washed in 
PBS 5 times for 5 minutes each wash. Then Alexa Fluor® goat anti-rabbit was added at 
1:1000 concentration and the coverslips were incubated for 1 hours at room 
temperature in the dark. The secondary anti-body was removed and the coverslips were 
washed 5 times for 5 minutes each with PBS in the dark. To mount coverslips, the edge 
was blotted on tissue paper to dry off excess liquid and cell side was placed down on 
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drop of mounting media (VECTASHIELD Mounting Medium with DAPI) on glass slide. 
The coverslip were stabilized on slide using nail polish and left to dry overnight before 
viewing. The images were captured usingAxivoert fluorescence microscope. In this 
experiment, cells were treated in triplicate for each experimental condition and pictures 
of five areas of each well were taken. 
 
RNA extraction.  
 
hCMEC/D3 cells were seeded at a concentration of 2 × 10⁵  cells/ml in 2×T75 flasks 
and incubated in complete medium for 24 hours. After 24 hours incubation, the medium 
was removed and replaced with SPM and incubated for 24 hours in normoxia. One flask 
was treated with 10 µM concentration of citicoline and the other was not treated, then 
both flasks were incubated in 1% O2 hypoxia for 24 hours. The cells were then 
trypsinized and the cell pellet was kept in ladled Eppendorf tubes at -80 °C to be used 
later in RNA extraction. The RNA extraction was done using RNeasy® Mini Kit. DNase I 
stock solution was prepared by injecting 550 μl RNase-free water into the DNase I vial 
using an RNase-free needle and syringe, and mixed gently by inverting the vial.350 μl of 
RLT buffer was added to each cell pellet, and centrifuged for 15 s at ≥8000 x g (≥10,000 
rpm). 10 μl DNase I stock solution was added to 70 μl Buffer RDD and mixed gently by 
inverting the tube, then centrifuged briefly. DNase I incubation mix was added (80 μl) 
directly to RNeasy column membrane, and place on bench-top (20–30°C) for 15 min. 
700 μl of theRW1 buffer was added to the RNeasy spin column. The lid was closed, and 
centrifuged for 15 s at ≥8000 x g. The flow-through was discarded. 500 μl of the RPE 
buffer was added to the RNeasy spin column, and centrifuged for 15 s at ≥8000 x g. 
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The flow-through was discarded. 500 μl of the RPE buffer was added to the RNeasy 
spin column, and centrifuged for 15 s at ≥8000 x g. The flow-through was discarded. 
The RNeasy spin column was placed in a new 1.5 ml collection tube. 30 μl RNase-free 
water was added directly to the spin column membrane and centrifuged for 1 min at 
≥8000 x g to elute the RNA. 
 
Quantification of nucleic acid. 
 
The upper and lower optical surfaces of the NanoDrop were cleaned using Kimwipe 
before loading the samples. 1µl of each sample was loaded onto the lower optical 
surface. Once the instrument lever arm was lowered, the upper optical surface started 
to engage with the sample forming a liquid column with the path length defined by the 
gap between the two optical surfaces. During each measurement, the sample was 
evaluated at both 1-mm and 0.2-mm path, providing a large dynamic range of nucleic 
acid detection. The measurements were evaluated using NanoDrop software.  
cDNA Synthesis Using the RT² First Strand Kit.  
The reagents of the RT² First Strand Kit were thawed, and briefly centrifuged (10–15 s) 
to bring the contents to the bottom of the tubes. The genomic DNA elimination mix for 
each RNA sample was prepared by adding 5 µg of RNA to 2 µl of GE buffer and RNA-
free water. Mixed gently by pipetting up and down and then centrifuged briefly. The 
genomic DNA elimination mix was incubated for 5 min at 42°C, then placed immediately 
on ice for at least 1 min. The reverse-transcription mix was prepared by mixing 8 µl 5x 
BC3 buffer, 2 µl P2 control, 4 µl RE3 reverse transcriptase mix, and 6 µl RNase-free 
water.10 µl reverse-transcription mix was added to each tube containing 10 µl genomic 
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DNA elimination mix. Mixed gently by pipetting up and down. Incubated at 42°C for 
exactly 15 min. Then immediately the reaction was stopped by incubating at 95°C for 5 
min. 91 µl RNase-free water was added to each reaction and mixed by pipetting up and 
down several times. The reactions were placed on ice.  
 
PCR microarray.  
 
The Human Apoptosis RT² Profiler PCR Array profiles the expression of 84 key genes 
involved in programmed cell death. This array includes TNF ligands and their receptors, 
members of the bcl-2, caspase, IAP, TRAF, CARD, death domain, death effector 
domain, and CIDE families, as well as genes involved in the p53 and DNA damage 
pathways. The experiment was carried out by first centrifuging the RT² SYBR Green 
Mastermix briefly (10–15 s) to bring the contents to the bottom of the tube. The PCR 
components mix was prepared in a 5 ml tube by mixing 1350 µl 2x RT² SYBR Green 
Mastermix, 102 µl cDNA synthesis reaction, and1248 µl RNase-free water. The RT² 
Profiler PCR Array was carefully removed from its sealed bag. 25 µl PCR components 
mix was added to each well of the RT² Profiler PCR Array. The RT² Profiler PCR Array 
was tightly sealed with optical adhesive film. Centrifuged for 1 min at 1000 g at room 
temperature (15–25°C) to remove bubbles. The plate was visually inspected from 
underneath to ensure no bubbles are present in the wells. The real-time cycler was 
programmed according to table below. 
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Cycles Duration Temperature 
1 10 min 95°C 
40 15 s 
1 min 
95°C 
 60°C 
 
Table 5. The real-time cycler settings.  
 
The RT2Profiler PCR Array was placed in the real-time cycler and the run was started. 
Threshold cycle (CT) was calculated for each well using the real-time cycler software.  
Kinexusphospho-protein array analysis. 
 
Cells were seeded in 6-well plate at a concentration of 3 x 10⁵  cells / ml in complete 
medium. After 48 h incubation, the medium was replaced with SPM for further 24 h 
incubation then 10 µM of citicoline was added to the cells for 10 min stimulation at 37°C 
and one well was used for control (untreated cells). Proteins were extracted according 
to Kinetworks instructions. Briefly, cells were washed twice with cold PBS. Protein was 
extracted using a buffer (pH 7.2) containing 20 mM 3-(N-morpholino) propanesulfonic 
acid (MOPS), 2mM EGTA, 5 mM EDTA, 30 mM sodium fluoride, 60 mM β- 
glycerophosphate, 20 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 1 
mMphenylmethylsulfonylfluoride, 3mM benzamidine, 5 µM pepstatin A, 10 µM 
leupeptin, 1% Triton X-100 and 1 mM dithiothreitol on ice for cell lysis. Cell extracts 
were then collected and protein concentrations were measured by the Bradford protein 
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assay according to the manufacturer’s instructions (Bio-rad, Munchen, Germany). For 
each sample, protein (100 µg in 50 µl) was transferred to a fresh 1.5 ml Eppendorf 
screw cap then sent to Kinexus (Bioinformatics Corporation, Vancouver, Canada) to 
investigate the proteins involved in citicoline signalling pathways.   
Statistical analysis.   
 
Statistical analysis was made through using Microsoft Excel 2007 program. The results 
of each experiment determined as the mean ± Standard Deviation. Data shown were 
analysed for significance using one way ANNOVA and Student t-test. Differences with p 
values ≤0.05 were considered statistically significant. Each experiment was repeated at 
least three times.  
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Chapter 3 Results 
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Angiogenesis. 
 
Kinexus Assay. 
 
Figure 12. The Kinexus antibody microarray screen performed by Kinexus on BAEC. It showed 
a notable increase (> 100 %) of the phosphorylation of ASK-1, HER-2, IRS-1 and Jun and an 
inhibition (< 50%) for Hsp-70, Integrin alpha4, MEK-1 and Histone H2B proteins. 
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Pro-angiogenic effects of citicoline on hCMEC/D3 proliferation, migration and 
tube formation. 
 
Generally, there are three classes of additives that are required in the growth medium of 
cells to obtain continuous proliferation in vitro. The first class include nutrients such as 
glucose, amino acids, vitamins, iron, cobalt, manganese and selenium. The second 
class include cell adhesives which enable cells to attach to solid surfaces such as 
fibronectin, collagen and vitronectin. The third class of additives is serum which acts as 
a source of growth factors (Heath, 2008). Growth factors, cytokines, mitogens, 
hormones, and oxidative or heat stress are extracellular stimuli that can activate ERK1 
and ERK2. Extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) are 
members of the mitogen-activated protein kinase super family that can mediate cell 
proliferation and apoptosis (Cobb et al., 1995, Tesfaigzi et al., 2009). Treatment with 
citicoline stimulates the phosphorylation of ERK, therefore it could play a role as a 
mitogen. However, in this study, citicoline had no mitogenic effect on hCMEC/D3 cells 
when the cell proliferation assay was performed. 
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Condition Cell Number 
×10⁴  
SD ×10³ Percentage 
increase 
P Value 
Control 13.6 14.1   
1 µM 
Citicoline 
15.4 15.3 13% 0.34 
5 µM 
Citicoline 
17.6 7.2 29% 0.18 
10 µM 
Citicoline 
24.4 23.2 78% 0.16 
 
Table 6. The effects of citicoline on hCMEC/D3 cells proliferation were determined and 
show statistically a non-significant increase in number of cells compared to control.  
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Pro-angiogenic effects of citicoline on hCMEC/D3 tube formation. 
HER-2 inhibition. 
 
Human epidermal growth factor receptor HER-2 plays an important role in cellular 
process including proliferation, metastasis, and angiogenesis. It is also found to be 
overexpressed in tumourigenesis and implicated in different types of cancers including 
gastric, prostate and breast cancer. HER-2 is mainly activated through 
heterodimerization with other members of the epidermal growth factor receptor (EGFR) 
family which causes downstream signalling through the Ras and phosphoinositide-3-
kinase pathways. HER-2 inhibition has been a major interest as therapeutic strategy in 
cancer treatment (Boone et al., 2009, Slamon et al., 2001, Gomez-Martín et al., 2014). 
Overexpression of HER-2 in cancer is associated with aggressive histology, poor 
prognosis, and unresponsiveness to the standard endocrine therapies and shorter 
survival (Bauer, 2007). In view of the importance of the HER-2 pathway in the 
pathogenesis of breast cancer, there has been major interest on the inhibition of this 
pathway as a therapeutic strategy (Moasser et al., 2001). GW2974 is a quinazoline 
derivative, which acts as an inhibitor of HER-2. In animal model of biliary tract cancer 
(BCT), GW2974 treatment as a supplement in the diet showed a potent chemo-
preventive and therapeutic effect (Kiguchi et al., 2005). 
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Figure 13. Chemical structure of GW2974 (Sodani et al., 2012). 
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      Control    10 µM        5 µM        1 µM     
 
 
 
 
 
 
Figure 14. Representative western blot showing HER2 expression in cells untreated and treated 
with different concentrations of citicoline (1 µM, 5 µM and 10 µM). Treatment with 10 µM 
citicoline increased the expression of HER2 by 545.2% compared to control. Cells treated with 5 
µM citicoline showed a 348.3% increase in HER2 expression compared to untreated cells. In 
cells treated with 1 µM citicoline, there was a 348.4% increase in HER2 expression compared to 
control. 
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Figure 15. Representative western blot showing pilot experiment to determine optimal 
HER2 inhibitor concentration. HER2 expression was induced with 10 µM citicoline which 
increased the expression of HER2 by 208.5% compared to control. Cells treated with 10 
µM citicoline in combination with 5 µM HER2 inhibitor showed a 70.9% decrease in 
HER2 expression compared to cells treated with10 µM citicoline. In cells treated with 10 
µM citicoline in combination with 1 µM HER2 inhibitor, there was a 72.4% reduction in 
HER2 expression compared to cells treated with 10 µM citicoline.  
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Erk 1/2.   
 
The extracellular signal-regulated kinase (ERK) family belongs to the mammalian MAP 
kinases, and the activated MAP kinases catalyze the phosphorylation of numerous 
substrate proteins. ERK1 and ERK2 are related protein-serine/threonine kinases which 
are 84% identical in sequence and share many if not all functions, and therefore, they 
are referred to as ERK1/2. They are involved in the Ras-Raf-MEK-ERK signal 
transduction cascade which regulate of a wide range of processes including cell 
adhesion, cell cycle progression, cell migration, cell death, differentiation, metabolism, 
cell proliferation and growth, and transcription (Jr. et al., 2012, Schramek, 2002). They 
are 44- and 42-kDa proteins that phosphorylated a multitude of protein substrates and 
are expressed in almost all tissues (Tesfaigzi et al., 2009). In endothelial cells, hypoxia 
induces the activation of several components of signal transduction pathways. Members 
of the mitogen activated protein kinase MAPK superfamily, consisting of extracellular-
related kinase ERK1/2 have been shown to be activated by hypoxia (Kroon et al., 
2000).  FGFs belong to a family of heparin-binding polypeptide growth factors that have 
over 20 members, including FGF-2. FGF-2, which has been shown to promote 
endothelial cell modifications associated with angiogenesis (Kim et al., 2014). The 
binding of FGF2 to its tyrosine-kinase receptors triggers downstream signalling which 
involves the activation of mitogen-activated protein kinase (MEK) with consequent 
phosphorylation of extracellular signal-regulated kinases (ERKs) (Giuliani et al., 1999). 
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Figure 16. Representative western blot showing 25 ng FGF-2 and 10 µM citicoline effect on 
pErk expression with and without 5 µM HER2 inhibitor.  P-Erk was expressed within similar 
range in cells treated with 25 ng FGF-2 and 25 ng FGF-2 in combination with Her2 inhibitor. P-
Erk was also expressed in cells treated with 10 µM citicoline but in cells treated with 10 µM 
citicoline in combination with Her2 inhibitor p-Erk was not expressed. 
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Optimisation of cell differentiation assay (Matrigel™ 3D-tube formation).  
Determine cell concentration for tube formation assay 
 
A) Control Cells. 
 
 
 
 
 
 
 
B) 25 ng FGF-2.                                                                             C) 10 μM Citicoline. 
 
 
 
 
 
 
 
 
Figure 17. Citicoline (10 μM) significantly increased the formation of tube-like structures of 
HCMEC/D3 with a stronger effect than fibroblast growth factor-2 (FGF-2).A) Control cells. B) 
Cells treated with FGF-2 (25 ng/ml). C) Cells treated with Citicoline. The tubes structures are 
clearly shown in the box exerted. 
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Figure 18. Representative examples of the effect of citicoline on tube formation with or without 
Her-2 inhibitor in comparison to FGF-2, FGF-2 + Her-2 inhibitor, and control cells. 
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Figure 19. Pro-angiogenic effects of citicoline and FGF-2 on hCMEC/D3 tube formation. The bar 
graph shows the stimulatory effects of citicoline 10 μM, and FGF-2 (25 ng /ml). It also shows the 
inhibitory effect of Her-2 inhibitor (GW2974) on tube formation by blocking the stimulatory effect 
of citicoline. In combination with FGF-2, Her-2 inhibitor did not show inhibitory effect on FGF-2 
activity. The bars represent the standard deviations. Experiments were performed in triplicate 
wells and repeated at least three times.  
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Pro-angiogenic effects of citicoline on hCMEC/D3 migration. 
 
hCMEC/D3 Cells were treated with different concentrations of citicoline (1 μM, 5 μM, 10 
μM) prior to a 24 hours incubation in stroke mimicking conditions (hypoxia). Pictures 
were taken at time 0 and then after 24 hours to capture the differences in number of 
cells migrated. In comparison to control, treatment with 1 μM citicoline increased the 
number of cells migrated towards the wound site by 130% (P<0.001). Treatment with 5 
μM citicoline increased the number of cells migrated by 450% (p < 0.001) in comparison 
to control. Treatment with 10 μM citicoline showed the most cell movement and 
increase in number of cells migrated (810%) compared to control cells (P < 0.001). The 
increase in number of migrated cells has been demonstrated to increase as citicoline 
concentration increased. 
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Figure 20. A) Control (untreated) cells in hypoxia. B) 1 μM citicoline treated cells in hypoxia. C) 
5 μM citicoline treated cells in hypoxia. D) 10 μM citicoline treated cells in hypoxia. 
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Figure 21. Pro-angiogenic effects of citicoline on hCMEC/D3 cell migration. After 24 hours 
incubation in hypoxia, citicoline in different concentrations (1 μM, 5 μM, 10 μM) showed a 
significant increase in number of cells migrated. The bars represent the standard deviations. 
Experiments were performed in triplicate wells and repeated at least three times. 
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Apoptosis. 
 
Protective effect of citicoline against hypoxia induced DNA damage in endothelial 
cells. 
 
hCMEC/D3 cells were treated with different concentration of citicoline (1 μM, 5 μM, 10 
μM) prior to 24 hours incubation in hypoxia along with control (untreated) cells. PI 
staining was used to detect the apoptotic cells. PI is usually excluded from surviving 
cells and used to identify dead cells in a population. Cells were observed using 
fluorescence microscopy with two filter; DAPI fluorescent filter, and rhodamine filter with 
x40 magnification. Cells were considered apoptotic when they displayed signs of 
apoptosis such as condensation of nuclear materials, incorporation of PI stain (red 
colour) into the nucleus, disruption of cell cytoplasm and shrinkage of the cells. The 
normal cells appeared swollen with round clear blue nuclei. 
 
 
 
 
 
 
 
 
 
 
 
100 | P a g e  
 
 
 
 
 
 
Figure 22. A) Control untreated cells in hypoxia. B) 1μM citicoline treated cells in 
hypoxia. C) 5μM citicoline treated cells in hypoxia. D) 10 μM citicoline treated cells in 
hypoxia. 
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Figure 23. Quantitative analysis of the apoptotic cells in percentage. Cells treated with different 
concentrations of citicoline (1 μM, 5 μMm, 10 μM) in hypoxia conditions. Compared to control, 
treatment with 10 μM citicoline showed the highest reduction (99.4%) in number of P.I positive 
cells. Treatment with 5 μM citicoline showed a 95% reduction in number of P.I positive cells 
compared to untreated cells. 1 μM citicoline treatment showed a reduction of 68% in 
comparison to control. The bars represent the standard deviations. Experiments were 
performed in triplicate wells and repeated at least three times. 
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Figure 24. A) Control untreated cells in normoxia. B) 1µM citicoline treated cells in normoxia. C) 
5 µM citicoline treated cells in normoxia. D) 10 µM citicoline treated cells in normoxia. 
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Western Blotting.  
 
α-tubulin, is an intracellular subunit of tubulin protein that is common in eukaryotes and 
makes up microtubules which are a component of the cytoskeleton and is involved in 
determining cell structure and providing platforms for intracellular transport, including 
some forms of cell locomotion, the intracellular transport of organelles, and the 
separation of chromosomes of during mitosis and meiosis (Ndhlovu et al., 2011, Cooper 
et al., 2000). In Western blotting, it is essential to correct for protein loading and factors, 
such as transfer efficiency using normalization against (housekeeping proteins) 
(Ferguson et al., 2005). Therefore, in this study, alpha tubulin was used as a loading 
control for Western blotting. 
PARP expression.  
 
Poly (ADP-ribose) polymerase 1 (PARP-1), also known as ARTD1 (diphtheria toxin-like-
ADP-ribosyltransferase), is a nuclear enzyme that is involved in both neuronal death 
and survival triggered by stress. PARP-1 is the most abundant of numerous PARP 
family members, accounting for more than 85% of nuclear PARP activity, and is present 
in all nucleated cells of multi-cellular animals (Castri et al., 2014, Kauppinen et al., 
2007). 
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                       Normoxia                                                    Hypoxia 
       Control       10 µM        5 µM         1 µM              Control       10 µM        5 µM         1 µM 
 
 
 
 
Figure 25. Representative Western blot showing the effect of citicoline on PARP expression in 
normoxia and hypoxia. In normoxia the expression of uncleaved PARP showed equal ranges 
across all conditions including control (untreated) cells, 1 μM citicoline, 5 μM citicoline, and 10 
μM citicoline. Active PARP in normoxia is showing a very low expression. In hypoxia condition, 
the level of un-cleaved PARP expression varied among all conditions with 10 μM citicoline 
treated cells showing the highest (214.5%) increase of uncleaved PARP expression compared 
to control cells. In cells treated with 5 μM citicoline, the level of PARP expression showed a 
19.0% increase compared to control condition. In cells treated with 1μM citicoline, the level of 
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PARP expression showed a 10% increase compared to control condition. In hypoxia condition, 
the level of cleaved PARP expression varied among all conditions with 10 μM citicoline treated 
cells showing the highest 100% reduction of cleaved PARP expression compared to control 
cells. In cells treated with 5 μM citicoline, the level of cleave PARP expression showed a 38.9% 
reduction compared to control condition. In cells treated with 1μM citicoline, the level of cleaved 
PARP expression showed a 23.1% decrease compared to control condition. 
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Caspase-3 expression. 
Caspases, also known as interleukin 1β-converting enzyme (ICE)-like proteases play 
key biological roles in inflammation and mammalian apoptosis (Porter et al., 1997, 
Alnemri et al., 1996). The most intensively studied apoptotic caspase is caspase-3, 
which normally exists in the cytosolic fraction of cells as an inactive precursor that is 
activated by proteolysis during apoptotic cell death (Liu et al., 1997). Caspase-3 can be 
activated by multiple apoptotic signals including the activation of the cell receptor Fas 
(Apo-1/CD95). The protein Bcl-2 regulates Fas signalling which in turn activates the 
initiator caspases such as caspase-8 and caspase-10, and at the end activates 
executor caspase-3 (Hua et al., 2005). Capsapse-3 can also be activated by cytotoxic T 
lymphocytes (CTL). CLTs are critical effector cells of the immune system and they kill 
their target cells mainly by induce cell death through FAS-mediated pathway (Jerome et 
al, 2003, Bleackley et al., 2002). Variety of pharmacological agents can also activate 
caspase-3 including oleanane triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid 
(CDDO) and 1-beta-D-arabinofuranosylcytosine. They both inhibit growth and 
differentiation of human myeloid leukemia cells and induce apoptosis through caspase-
3 pathway (Ito, 2000). Caspase-3 expression and enzymatic activity can be inhibited by 
M826 (3-({(2S)-2-[5-tert-butyl-3-{[(4-methyl-1,2,5-oxadiazol-3-yl)methyl]amino}-2-
oxopyrazin-1(2H)-yl]butanoyl}amino)-5-[hexyl(methyl)amino]-4-oxopentanoic acid). 
M826 potently inhibited both caspase-3 enzymatic activity and apoptosis in cultured 
cells in vitro and it provided a significant reduction (66%) in the number of neurons 
expressing active caspase-3 in rat model. In a rat model of neonatal hypoxic-ischemic 
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(H-I), M826 blocked caspase-3 activation, cleavage of its substrates and significantly 
reduced DNA fragmentation and brain tissue loss (Toulmond et al., 2004, Han et al., 
2002). 
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                            Normoxia                                                      Hypoxia 
           Control     10 µM     5 µM     1 µM               Control     10 µM     5 µM     1 µM 
 
 
 
 
 
 
 
Figure 26. Representative Western blot showing showing the effect of citicoline on caspase 3 
expression in normoxia and hypoxia. In normoxia, there was no expression of active caspase 3. 
In hypoxia condition, the level of caspase-3 varied among all conditions with 10 μM citicoline 
treated cells showing the highest (79.6%) reduction of active caspase-3 expression compared to 
control cells. In cells treated with 5 μM citicoline, the level of active caspas-3 expression showed 
a 79.5% decrease compared to control condition. In cells treated with 1μM citicoline, the level of 
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active caspase-3 expression showed a 75.2% reduction compared to control condition. The 
expression of total caspase-3 showed values within similar ranges across all conditions 
including control (untreated) cells, 1 μM citicoline, 5 μM citicoline, and 10 μM citicoline. 
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H2B Ser14 expression. 
Histone proteins are major components of DNA in eukaryotic cells, and therefore, 
chromatin condensation which is one of the hallmark characters of apoptosis could be 
regulated by posttranslational histone modifications. Phosphorylation of histone H2B at 
serine 14 (S14) has been reported to be associated with cells undergoing programmed 
cell death in vertebrates (Cheung et al., 2003). In mammalian cells, the serine 14 
residue in the NH2-terminal tail of histone H2B is rapidly phosphorylated at sites of DNA 
double-strand breaks (DSBs). This phosphorylation is mediated by sterile 20 kinase 
(Mst1) and is well known for its role during apoptosis. In a study, it has been reported 
that H2B-Ser14P and H2AX work in cooperation to form a heterochromatin-like state 
within which both damaged DNA and trigger DNA damage response (Fernandez-
Capetillo et al., 2004, Altaf et al., 2007). 
 
Figure 27. Apoptotic stimulation activates caspases which in turn activates Mst1. Mst1 is 
activated by caspases upon exposure to apoptotic stimuli. The activated Mst1 translocates to 
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the nucleus and phosphorylates histone H2B at Ser 14, which causes the obstruction of 
regulator of chromosome condensation (RCC1) mobility. 
RCC1 impairment confines it in a binary complex with RAs-related nuclear protein (Ran), which 
affects the production of free RCC1 to catalyse another round of nucleotide transport. 
Consequently, RanGTP production is affected. The diminished level of nuclear RanGTP causes 
inactivation of the nuclear transport machinery. As a consequence, NLS containing proteins, 
including NF-kappaB–p65, remain bound to importins alpha and beta in the cytoplasm (Wong et 
al., 2009). 
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                      Normoxia                                                   Hypoxia 
        Control     10 µM       5 µM       1 µM         Control     10 µM    5 µM    1 µM 
 
 
 
 
 
 
Figure 28. Representative Western blot showing the effect of citicoline on H2B expression in 
normoxia and hypoxia. There was an equal level of H2B and no H2B Ser14 expression in 
normoxia. In hypoxia condition, the level of H2B Ser14 expression varied among all conditions 
with 10 μM citicoline treated cells showing 56.7% reduction of H2B Ser14 expression compared 
to control cells. In cells treated with 5 μM citicoline, the level of H2B Ser14 expression showed a 
44.5% decrease compared to control condition. In cells treated with 1μM citicoline, there was a 
64.4% reduction compared to control. 
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Immunofluorescence. 
Active caspase-3. 
Active caspase-3 expression was measured in hCMEC/D3 cells treated with different 
concentrations of citicoline (1 μM, 5 μMm, 10 μM) in hypoxia and normoxia conditions. 
After 24 hours, cells were stained with active caspase-3 antibody and photographed 
using fluorescence microscope. Cells in hypoxia conditions showed different levels of 
active caspase-3 expression, whereas in normoxia conditions, there was no visible 
expression of active caspase-3.  
 
Figure 29. Active caspase-3 expression in cells treated with different concentrations of citicoline 
(1 μM, 5 μM, 10 μM) in hypoxia conditions. The intensity of fluorescence, which was measured 
using fluorescence microscope, is equivalent to the level of protein expression. Compared to 
control, treatment with 10 μM citicoline showed the highest reduction (72.2%) in caspase-3 
expression. Treatment with 5 μM citicoline showed a 65.8% reduction in caspase-3 expression 
0
5
10
15
20
25
30
35
40
45
50
Control 1 µM Citicoline 5 µM Citicoline 10 µM Citicoline
A
ct
iv
e 
C
as
p
as
e 
3
 E
xp
re
ss
io
n
*p<0.01 
* 
* 
* 
114 | P a g e  
 
compared to untreated cells. 1 μM citicoline treatment showed a reduction of 53.1% in 
comparison to control. The bars represent the standard deviations. Experiments were 
performed in triplicate wells and repeated at least three times. 
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Figure 30. Control (untreated) cells in hypoxia. 
 
Figure 31.1 µM citicoline treated cells in hypoxia conditions. 
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Figure 32. 5 µM citicoline treated cells in hypoxia conditions. 
 
 
 
 
 
 
 
 
 
Figure 33. 10 µM citicoline treated cells in hypoxia conditions. 
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Figure 34. Control cells in normoxia conditions. 
 
Figure 35. 1 µM citicoline treated cells in normoxia conditions. 
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Figure 36. 5 µM citicoline treated cells in normoxia conditions. 
 
Figure 37. 10 µM citicoline treated cells in normoxia conditions. 
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H2B Ser14. 
H2B Ser14 expression was measured in hCMEC/D3 cells treated with different 
concentrations of citicoline (1 μM, 5 μMm, 10 μM) in hypoxia and normoxia conditions. 
After 24 hours, cells were stained with H2B Ser14 antibody and photographed using 
fluorescence microscope. Cells in hypoxia conditions showed different levels of H2B 
Ser14 expression, whereas in normoxia conditions, there was no visible expression of 
H2B Ser14.  
 
Figure 38. H2B Ser14 expression in cells treated with different concentrations of citicoline (1 
μM, 5 μMm, 10 μM) in hypoxia conditions. Compared to control, treatment with 10 μM citicoline 
showed the highest reduction (70%) in H2B Ser14 expression. Treatment with 5 μM citicoline 
showed a 53% reduction in H2B Ser14 expression compared to untreated cells.1 μM citicoline 
treatment showed a reduction of 45% in comparison to control. The bars represent the standard 
deviations. Experiments were performed in triplicate wells and repeated at least three times. 
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Figure 39. Control cells in hypoxia conditions. 
 
 
Figure 40. 1 µM citicoline treated cells in hypoxia conditions. 
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Figure 41. 5 µM citicoline treated cells in hypoxia conditions. 
 
Figure 42. 10 µM citicoline treated cells in hypoxia conditions. 
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Figure 43. Control cells in normoxia. 
 
 
 
 
 
 
 
 
 
 
Figure 44. 1 µM citicoline treated cells in normoxia conditions. 
123 | P a g e  
 
 
Figure 45. 5 µM citicoline treated cells in normoxia conditions. 
 
Figure 46. 10 µM citicoline treated cells in normoxia conditions. 
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Flow Cytometery. 
Using Flow Cytometry, the cell population treated with different concentrations of 
citicoline (1μM, 5 μM and 10 μM) in hypoxia conditions for 24 hours, were tested to 
measure the percentage of cells undergoing apoptosis or have already died. Once fixed 
the population is stained using Propidium Iodide (PI) which stains dead cells and a FITC 
labeled antibody (Annexin V) to phosphatidylserine (PS). PS is a phospholipid normally 
found inside the cell membrane, but which is transferred to the outer leaflet of the cell 
membrane and is used as an indicator of apoptosis. 
 
Figure 47. Percentage of late apoptotic cells treated with different concentrations of citicoline 
(1μM, 5 μM and 10 μM) in hypoxia and normoxia conditions. There was a 16% increase in the 
percentage of early apoptotic cells in 1 μM citicoline treated cells (p> 0.05) compared to 
untreated cells. In 5 μM citicoline treated cells, the percentage of early apoptotic cells decreased 
by 6% (p> 0.05), but increased by 25%  (p> 0.05) in 10 μM citicoline treated cells compared to 
control cells. In normoxia, there was a 14% decrease in the percentage of early apoptotic cells 
in 1 μM citicoline treated cells (p< 0.05) compared to untreated cells. In 5 μM citicoline treated 
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cells, the percentage of early apoptotic cells decreased by 34% (p< 0.05), and decreased by 
14% (p> 0.05) in 10 μM citicoline treated cells compared to control cells. The bars represent the 
standard deviations. Experiments were performed in triplicate wells and repeated at least three 
times.  
 
Figure 48. Percentage of early apoptotic cells treated with different concentrations of citicoline 
(1μM, 5 μM and 10 μM) in hypoxia and normoxia conditions. In hypoxia, there was a 19% 
decrease in the percentage of early apoptotic cells in 1 μM citicoline treated cells (p< 0.05) 
compared to untreated cells. In 5 μM citicoline treated cells, the percentage of early apoptotic 
cells decreased by 2% (p> 0.05), but increased by 16% (p> 0.05) in 10 μM citicoline treated 
cells compared to control cells. In normoxia, there was a 17% increase in the percentage of 
early apoptotic cells in 1 μM citicoline treated cells (p< 0.05) compared to untreated cells. In 5 
μM citicoline treated cells, the percentage of early apoptotic cells increased by 4% (p> 0.05), but 
decreased by 9% (p> 0.05) in 10 μM citicoline treated cells compared to control cells. The bars 
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represent the standard deviations. Experiments were performed in triplicate wells and repeated 
at least three times. 
 
Figure 49. Flow charts of control cells in hypoxia conditions. Lower right quadrant, annexin V 
positive and PI negative cells indicate early apoptotic cells; upper right quadrant, annexin V and 
PI-positive cells represent necrotic or late apoptotic cells. Lower left quadrant annexin V 
negative and PI negative cells indicate live cells; upper left quadrant annexin V negative and PI 
positive cells indicate dead cells. 
 
 
 
 
 
 
127 | P a g e  
 
 
Figure 50. 1 μM citicoline treated cells in hypoxia conditions. 
 
Figure 51. 5 μM citicoline treated cells in hypoxia conditions. 
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Figure 52. 10 μM citicoline treated cells in hypoxia conditions. 
 
 
 
 
 
 
 
 
Figure 53. Control cells in normoxia conditions. 
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Figure 54. 1 μM citicoline treated cells in normoxia conditions. 
 
 
Figure 55. 5 μM citicoline treated cells in normoxia conditions. 
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Figure 56. 10 μM citicoline treated cells in normoxia conditions. 
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Real Time PCR. 
Real-time RT-PCR is a very sensitive and reliable technique to analyse gene 
expression. It allows the detection of the expression of a wide range of genes in the 
same sample simultaneously, due to the combination of real-time PCR and microarrays. 
The RT² Profiler PCR Array used in this study was designed to analyse a panel of 
genes related to the apoptotic pathway. 
 
Figure 57. Relative gene expression between control cells and cells treated with 10 μM citicoline 
was calculated using qRT-PCR (GAPDH, HPRT1 and RPLPO were taken as endogenous 
control). The results show a significant decrease in caspase 9 expression with 10 μM citicoline 
treatment. Expression of neuronal apoptosis inhibitory protein (NAIP), Nucleotide-binding 
oligomerization domain-containing protein 1(NOD1), tumour necrosis factor receptor 
superfamily member 25 (TNFRSF25) and tumour protein p53 (TP53) was induced by 10 μM 
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citicoline treatment. There was also a reduction in the expression of BCL2/adenovirus E1B 19 
kDa protein-interacting protein 3(BNIP3), BCL2/adenovirus E1B 19 kDa protein-interacting 
protein 3-like (BNIP3L), caspase 4, caspase 8, protein cell death-inducing DFFA-like effector B 
(CIDEB), Lymphotoxin-beta receptor (LTBR), pentapetide thymopentin Binding Protein 2 
(TP5BP2), tumor necrosis factor receptor type 1-associated DEATH domain protein (TRADD), 
and TNF receptor-associated factor 3 (TRAF3). 
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Chapter 4 Discussion 
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Discussion. 
Despite the significant scientific approaches on the clinical as well as on the 
experimental level, ischemic stroke treatment is still based on general intensive care 
procedures and on reperfusion therapy with recombinant tissue plasminogen activator 
(rtPA). RtPA improved functional outcome in patients treated soon after acute ischemic 
stroke in randomized trials. However, reperfusion has definite risks. It brought 
devastating results for some patients in the form of fatal edema or intracranial 
hemorrhage following thrombolysis. Reperfusion after a long period of ischemia can 
cause a larger infarct than that linked to permanent vessel occlusion in some animal 
stroke models. Therefore, while reperfusion may reduce infarct size and enhance 
clinical outcome in some patients, in others it may aggravate the brain injury and 
produce cerebral reperfusion injury. Moreover, rtPA treatment does not suit a wide 
spectrum of stroke patients and it must be administered within a 4.5 h window after the 
onset of symptoms due to an increasing risk of hemorrhage. Therefore, novel 
therapeutic options for ischemic stroke are urgently needed (Kleinschnitz et al., 2012, 
Pan et al., 2007). 
In combination with thrombolytic agents such as rtPA, citicoline shows a significant 
reduction of infarct size in a rat model of focal Ischemia. It reduces cell damage after 
transient forebrain ischemia, prolongs the duration of ischemia required to produce a 
given behavioural deficit or infarct size and improves neurological recovery. Moreover, 
citicoline has potential in reducing neurological deficits resulting from ischemic stroke in 
humans. In clinical trials citicoline improves cognitive and behavioural parameters and 
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function on neurological levels in ischemic stroke patients (Krupinski et al., 2002, 
Overgaard, 2014). 
Moreover, in one study, citicoline treatment demonstrated a reduction in Cerebral WM 
(white matter) lesions and apoptosis compared to control group. The study was 
conducted by experimentally inducing white matter lesions (which can be caused by 
chronic cerebral ischemia) in the rat brain by permanent occlusion of both common 
carotid arteries, which can affect cognitive function, and this model is similar to that of 
vascular dementia. This technique induces certain learning disorders by restricting the 
blood flow in the cerebral cortex and hippocampus by up to 40-82%8-10 for several 
months. Therefore, it can be used to study vascular dementia and cerebral WM lesions 
(Lee et al., 2009). 
In a similar study, the effect of CDP-choline on brain plasticity markers expression in the 
acute phase of cerebral infarct was examined in an experimental animal model. It was 
conducted by using Male Sprague-Dawley rats that were subjected to permanent 
middle cerebral artery occlusion (pMCAO) and treated or not with CDP-choline (500 
mg/kg) daily for 14 days starting 30 min after pMCAO. Subsequently, functional status, 
lesion volume, apoptosis, and cellular proliferation were measured. Citicoline 
significantly improved functional recovery and decreased lesion volume at 14 days 
compared to the control group. According to the data from the study, citicoline improved 
functional recovery after permanent middle cerebral artery occlusion in association with 
reductions in lesion volume and apoptosis. It increased cell proliferation, vasculogenesis 
and synaptophysin levels in the peri-infarct area of the ischemic stroke (Gutiérrez-
Fernández et al., 2012). A meta-analysis was conducted to assess the neuroprotective 
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actions of citicoline and the results showed  that  the weighted mean difference meta-
analysis showed a reduction in infarct volume by 27.8%,  citicoline effect on reducing 
infarct volume was higher in proximal occlusive models of middle cerebral artery (MCA) 
compared with distal occlusion in the stratified analysis, and the efficacy was superior 
using multiple doses than single dose and when a co-treatment was administered 
compared with citicoline monotherapy (Bustamante et al., 2012). 
However, a randomised, placebo-controlled, sequential trial in patients with moderate-
to-severe acute ischaemic stroke admitted at university hospitals in Germany, Portugal, 
and Spain was performed in 2012. This study showed that citicoline is not efficacious in 
the treatment of moderate-to-severe acute ischaemic stroke (Dávalos et al., 2012). 
The bioavailability of citicoline after oral administration is 100% and it has shown 
different pharmacological actions, with beneficial effects in some models of cerebral 
ischemia and collaborative effects with other drugs tested in the treatment of stroke. 
The clinical development of citicoline as a therapy for acute ischemic stroke was 
initiated in the United States in the 1990s. The first US phase II to III trial was performed 
to assess the effect of 3 doses (500, 1000, and 2000 mg/d) of citicoline against placebo. 
The results demonstrated significant improvement of neurological, functional, and global 
outcomes with citicoline treatment at 500 and 2000 mg/d compared with placebo 12 
weeks after stroke onset (Dávalos et al., 2002). Although citicoline was used as a form 
of ischemic stroke treatment in a number of trials since then, there are no other studies 
so far that have investigated the effect of citicoline modulation of angiogenesis related 
to stroke recovery. Understanding the mechanisms through which citicoline stimulates 
angiogenesis, has the potential of exploring its benefit in stimulating tissue remodelling 
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after ischemic stroke. Therefore, this study was designed to investigate the role of 
citicoline in modulation of angiogenesis. In case of stroke, treatment normally start after 
the incident, however, the laboratory restriction in this study was that the treatment with 
citicoline was prior to the placing of the cells in the hypoxia chamber which could not be 
opened once it was filled with hypoxia gas.  
Angiogenesis is a highly regulated process that is dependent on homogenous balance 
between pro-angiogenic and anti-angiogenic microenvironmental signals. Several 
studies have highlighted the important role of ERK activation in regulation of endothelial 
cell process during angiogenesis (Rizzo, 2007). In conjunction with this, Western 
blotting results demonstrated that citicoline induced pERK1/2 expression, a key 
mitogenic signalling protein known to be involved in angiogenesis and generally 
stimulated by growth factors through interaction with their receptors (Slevin et al., 2006). 
ERK2/ERK1 (also known as p42 ⁄p44MAPK, respectively, and officially named MAPK 1 
and 3) are two isoforms of extracellular signal-regulated kinase (ERK) that belong to the 
family of mitogen-activated protein kinases (MAPKs). The activation of ERK2⁄ERK1 by 
phosphorylation regulates several cytoplasmic and nuclear targets that are responsible 
for a number of important biological mechanisms such as proliferation, migration, 
differentiation and cell survival. In some cases, depending on the longitude and 
magnitude of activation, ERK activity has been involved in neurodegenerative diseases 
and brain injury following ischemia in animal models (Cagnol et al., 2010). 
Although this study established the effect of citicoline on ERK1/2 phosphorylation from 
Western blot analysis, citicoline was found to have no mitogenic effect using Human 
Cerebrovascular Microvessel endothelial cell (HCMEC/D3). Cells in cell proliferation 
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assay were treated in normoxia only because of the extended period of 72 hours which 
would be excessive in case of hypoxia. Moreover, from the data collected in this study, 
citicoline (10 μM) did not show a significant increase the proliferation of HCMEC/D3 
after 72 h incubation comparing to the untreated cells. These results are in agreement 
with published data demonstrating that citicoline had no effect on cell proliferation using 
a similar dose (Krupinski et al., 2012).  
It is hypothesized that citicoline modulates tube like structure formation and this study is 
the first to demonstrate that citicoline is highly angiogenic and therefore may contribute 
to the revascularization process aiding tissue recovery. It also demonstrated that 
citicoline (10 μM) was more effective in promoting the formation of tube-like structures in 
HCMEC/ than FGF-2 which is a well-known potent angiogenic factor. Since 
maintenance of angiogenesis is one of the keys to both short-term and chronic re-
vascularization after stroke, these findings could be very valuable for analysing the 
potential mechanisms through which citicoline treatment results in patient recovery. 
From Western blotting results, citicoline was also found to increase Her-2 expression. 
Therefore, GW2974, which is a Her-2 inhibitor, was used to inhibit Her-2 expression in 
order to determine the molecular pathway in which citicoline promoter tube formation. 
The results from Western blotting showed that citicoline treatment alone induced 
ERK1/2 expression but in combination with Her-2 inhibitor, ERK1/2 expression was 
blocked. However, when cells were treated with FGF-2 in combination with Her-2 
inhibitor, there was no effect on FGF-2 induced ERK1/2 expression demonstrating 
specifity of the inhibitor. 
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Moreover, one of the angiogenesis assays that can be conducted in vitro is the short-
term culture of endothelial cells in Matrigel™ , which is a gelatinous protein mixture, 
obtained from Engelbreth-Holm-Swarm mouse sarcoma cells. It is a fast and simple 
assay to perform and also provides in vitro demonstration of endothelial cell 
mechanisms including survival, apoptosis, and tube formation. It is also important for 
studying the effects of drugs on angiogenesis in vitro before these are developed into 
clinical treatments (Khoo et al, 2011). In a pilot study, citicoline was established to 
increase tube formation in HCMEC/D3. Therefore, in this study a tube formation assay 
was performed to confirm findings from Western blot results. The results showed an 
inhibitory effect of Her-2 inhibitor on tube formation by blocking the stimulatory effect of 
citicoline. In combination with FGF-2, Her-2 inhibitor did not show inhibitory effect on 
FGF-2 activity. Therefore, one of the novel findings that emerged from this study is the 
action of citicoline in promoting tube formation and Erk1/2 activation through Her-2 
receptor. 
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Figure 58. Proposed pathway of citicoline induced ERK1/2 expression. Binding of 
citicoline to HER-2 initiates a series of intracellular signals, including activation of Ras-
Raf-MEK-ERK pathway, which leads to induction of tube formation. Her-2 inhibition does 
not affect FGF-2 induced ERK1/2 expression since FGF-2 acts of FGFR receptor. 
 
Moreover, the results from the Kinexus antibody microarray screen showed a 
notable increase (> 100%) of the phosphorylation of HER-2. HER-2 is from a 
family of receptors that are expressed in various tissues of epithelial, 
mesenchymal and neuronal origin, and they are involved in regulating various 
cellular pathways such as proliferation, differentiation, migration and apoptosis 
(Olayioye, 2001). This protein, initially discovered as an activated oncogenic 
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variant, is overexpressed in many epithelial tumours including breast and ovarian 
cancers (Bourguignon, 2007). In breast cancer cells, overexpression of ErbB2 
(HER-2) leads to constitutive activation of the ERK and PI3K/Akt pathways 
(Chen, 2008). In addition, HER-2-overexpressing breast cancers tend to be more 
angiogenic than other breast cancers (Klos, 2000). High levels of Her-2 
expression is established to be associated with increase in angiogenesis (Kumar 
et al, 2001). Moreover, Her-2 is involved in the regulation of vascular endothelial 
growth factor (VEGF), which is one of the most potent inducers of angiogenesis 
that induces endothelial cell proliferation and migration. In human breast cancer, 
overexpression of Her-2 is associated with increased VEGF expression. 
Moreover, VEGF expression in human mammary tumours is associated with 
increased microvessel density and reduced survival rate (Klos et al., 2000). 
The ability of citicoline to activate intra-cellular signal transduction pathways and 
induce phosphorylation of down-stream angiogenic molecules was investigated 
using Kinexus-phospho-protein screen. Histone phosphorylation was studied in 
several mammalian cells undergoing apoptosis. After treating cells with a number 
of apoptotic inducers, H2B was found to be phosphorylated in cells undergoing 
apoptosis comparing to normal or growing cells (Ajiro, 2000). 
In this study; Kinxues results showed that H2B decreased ten times in the 
HCMEC/D3 stimulated with citicoline comparing to control untreated cells. 
Recently, phosphorylation of histone H2B at serine 14 (S14), a posttranslational 
modification required for nuclear condensation, has been established to be 
associated with apoptosis (Zhuang et al., 2007, Ajiro et al., 2010). Similarly, one 
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of the studies showed that apoptosis-specific histone H2B phosphorylation was 
highly elevated and DNA fragmentation activity in the cytoplasm was detected in 
cells that were undergoing apoptosis (Ajiro et al., 2004). 
Conversely, in this study, there was a notable increase (> 100%) of the 
phosphorylation of IRS-1 after treating cells with citicoline. Insulin receptor 
substrate 1 (IRS-1) is a member of adaptor proteins that link signalling from 
upstream activators to multiple downstream effectors to modulate normal growth, 
metabolism, survival, and differentiation (Dearth, 2007). Although IRS proteins 
signal through many pathways, their main function is regulation of the 
phospholipid kinase phosphatidylinositol 3-kinase (PI3-K) and extracellular signal 
regulated kinase (ERK) pathways (Houghton, 2011). PI3-K is known to link IGF-
IR signalling with the Akt/PKB activation pathway/s associated with cell 
protection from apoptosis. Activation of PI3-K regulates Akt, which is a serine-
threonine kinase that plays an important role in cell survival. Akt protection 
against apoptosis involves direct inhibition (phosphorylation) of pro-apoptotic 
signals such as Bad and FOXO3A (Pan et al., 2007).  
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Figure 59. The PI3K/Akt signalling pathway. Phosphorylation of Akt phosphorylates BAD and a 
non-active form of caspase-9. Phosphorylation of caspase-9 by phosphorylated Akt prevents 
formation of the apoptosome complex, and thus the downstream event of apoptosis is inhibited. 
(•) depicts chrysin (Khoo et al., 2010). 
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Caspases, which is a family of acting proteases, have been demonstrated to be 
overexpressed during focal and global ischaemia. After an ischaemic attack, neurones 
and glial cells in the infarcted core and in the penumbra zone surrounding it, tissue with 
obstructed glucose and oxygen supply, die progressively as the ischaemic injury initiate 
apoptosis. Although cerebral impairment resulting from ischaemia is only partly 
dependent on caspase initiation, caspase inhibition has been shown to be beneficial for 
tissue survival in several experimental models of cerebral ischaemia (Krupinski et al., 
2002). 
Along with several growth factors, VEGF activates PI3k by binding to its receptor, which 
is known to induce angiogenesis. Angiogenesis is crucial for the progression of normal 
physiological events, such as embryonic growth, as well as for pathogenic processes 
such as cancer. Angiogenesis can be induced by constitutively active PI3k and Akt, and 
therefore, inhibition of PI3k pathway restricts angiogenesis. Akt regulates several 
cellular mechanisms including cell survival, glycogen metabolism, cellular 
transformation, and myogenic differentiation. It is activated by PI3K through binding of 
its pleckstrin homology domain to the lipid products of PI3K and by phosphorylation at 
Thr-308 and Ser-473 residues by two phosphoinositide dependent protein kinases, 
PDK1 and PDK2 (Jiang et al., 2000). In acute ischemic lesions, inflammatory responses 
and injury to the endothelia of blood vessels have been detected simultaneously. 
Consequently, it is important to restore blood flow and protect neurons in order to 
reduce brain damage following an ischemic attack. Besides, extending the therapeutic 
window would be beneficial to treat a wider range of patients with acute brain ischemia 
(Nakase et al., 2011). 
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Figure 60. Ischemic cascade leading to cerebral damage. Ischemic stroke leads to 
hypoperfusion of a brain area that initiates a complex biochemical reactions. Excitotoxicity, 
oxidative stress, microvascular injury, blood-brain barrier dysfunction and postischemic 
inflammation lead to apoptosis in neurons, glia and endothelial cells. The extent and longitude 
of ischemia determines the volume of cerebral damage (Lakhan, 2009). 
In this study, results show an increase (> 100%) of the phosphorylation Apoptosis 
signal-regulating kinase 1 (ASK1) also known as mitogen-activated protein kinase 
kinase kinase 5 (MAP3K5). ASK1 is one of the main elements regulating reactive 
oxygen species (ROS) - induced JNK and p38 activation leading to differentially 
regulated apoptosis (Pressinotti et al., 2009). ROS, such as superoxide anion (O2•-), 
hydrogen peroxide (H2O2), and the hydroxyl radical (HO•), have several effects on 
major cellular mechanisms (Pan et al., 2010). Moreover, it has been reported that 
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during the cellular response to oxidant injury initiated by ROS, Akt is activated (Wang et 
al., 2000). ROS are produced as part of normal cellular metabolism and defence 
mechanisms and at low levels, they take part in regulation of cellular growth, 
differentiation, proliferation and apoptosis. Several biochemical and cellular reactions 
such as inflammatory response, increased ROS synthesis, damage of blood brain 
barrier and calcium overload are triggered by cerebral ischemia resulting from vascular 
diseases. With cerebral reperfusion, ROS synthesis is further activated leading to 
cytotoxicity through lipid peroxidation, oxidation of proteins and DNA fragmentation. It 
was demonstrated that ROS are synthesised upon ischemia onset in an animal model. 
Moreover, correlated cellular damage is parallel to the level of ROS. In addition, 
increased cerebrovascular permeability was established to be associated with the initial 
phase of reperfusion that can be reduced by inhibition of ROS production (Olmez et al., 
2012). These results highlight a possible signalling pathways through which citicoline 
modulates angiogenesis and apoptosis. Therefore, they portray citicoline as a possible 
therapeutic target for improving tissue recovery, revascularisation and neuro-protection 
in ischemic stroke. 
Propidium iodide (PI) has been used as DNA binding fluorescent dye to detect DNA 
damage. P.I binds to cell nuclei with fluorescence intensity that is correlated with the 
extent of DNA degradation. This is important because gradual degradation of inter-
nucleosomal DNA is a hallmark of apoptosis (Crompton et al., 1992). Uptake of the 
fluorescent exclusion dye P.I relies upon propidium iodide being impermeable to cells 
with an intact plasma membrane, however when cell integrity becomes compromised it 
becomes able to access the nucleus where it complexes with DNA rendering the 
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nucleus highly fluorescent (Brana et al., 2002). In his study, P.I staining was used to 
detect hypoxia induced DNA damage in HCMEC/D3 cells. A combination of DNA-
binding dye DAPI and PI were used to detect apoptotic cells under the fluorescence 
microscope. In this study, cells were considered apoptotic when displayed signs of 
apoptosis such as nuclear condensation, fragmentation, uptake of PI stain (red colour) 
into the nucleus, disruption of cell cytoplasm and distortion of the cells. The normal cells 
appeared swollen with round clear blue nuclei. For induction of in vitro ischemia, cells 
were incubated in hypoxia with oxygen concentration of <1.0%. The cells were treated 
with different concentrations of citicoline and incubated for 24 hours in hypoxia along 
with untreated cells. Dead cells were quantified by use of propidium iodide, and the 
results showed up to 34% reduction (P<0.001) in hypoxia induced DNA damage in cells 
treated with citicoline. Therefore, citicoline demonstrated a significant protective effect 
against hypoxia induced apoptosis. 
Although the experiment was repeated three times, the results from the flow cytometry 
did not show statistical significance and therefore considered to be inconclusive. In a 
study, Annexin V/PI staining has been found to lead to a significant number of false 
positive events (up to 40%), which are associated with PI staining of RNA within the 
cytoplasmic compartment (Rieger et al., 2010). Therefore, Annexin V/PI staining 
protocol could be modified to minimize error and to achieve more accurate results. The 
nucleosome is a basic unit of chromatin consisting of a segment of DNA wound around 
an octamer containing two copies of each H2A, H2B, H3, and H4 core histone. 
Posttranslational modifications of histone tails regulate numerous biological processes 
including transcription, DNA repair, and apoptosis. As a response to DNA damage, 
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serine 14 residue in the NH2-terminal tail of histone H2B is rapidly phosphorylated at 
sites of DNA double-strand breaks (Fernandez-Capetillo et al., 2004). 
In this study, phosphorylation of H2B at serine 14 residue in the NH2-terminal was 
examined in HCMEC/D3 undergoing hypoxia induced apoptosis to test the protective 
effect of citicoline against cell death. The results showed up to 78% inhibition of H2B 
Ser14 expression in cells treated with citicoline. H2B phosphorylation at serine 14 
(Ser14) is catalyzed by Mst1 kinase and has been linked to chromatin condensation 
during apoptosis. The activation of MAPKs (ERK1/2, JNK1/2 and p38) is regulated by 
caspase-3, which phosphorylates H2B at Ser14 leading to chromatin condensation 
during apoptosis (Lu et al., 2010). Therefore, in this study, the effect of citicoline on 
caspase-3 expression was examined and the results show an inhibition of up to 86% 
compared to untreated cells in hypoxia conditions. Activation of caspase 3 was induced 
by hypoxia which led to the activation of H2B phosphorylation at Ser14. For the first 
time, this study demonstrates that citicoline downregulates of H2B phosphorylation at 
Ser14 through caspase 3 pathway. In a previous study, caspase-3 activation has been 
linked to triggered necrosis and apoptosis, and exacerbated cerebral edema and 
neuronal death after intracerebral haemorrhage (Wang et al., 2013). In middle cerebral 
artery occlusion (MCAO) rats, treatment with citicoline 500 mg/kg intraperitoneally was 
found to decrease the expression of all procaspases, as well as the expression of 
cleaved caspase-3. This was accompanied by a reduction in the number of cells 
bearing nuclear DNA fragments. The expression of caspase-cleaved products of PARP 
(PARP 89 kDa) was reduced in citicoline-treated ischaemic rats (Krupinski et al., 2002). 
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PARP-1catalyzes poly-ADP ribosylation which is a posttranslational modification and is 
one of the initial cellular responses to DNA damage. It binds to the damage sites and is 
activated auto-modification which causes chromatin de-condensation around damage 
sites, recruitment of repair machineries such as DNA ligase III–XRCC-1 base excision 
repair complexes, and enhance rapid DNA damage repair, especially in the case of 
single-strand breaks (SSBs) (Sugimura et al., 2008). 
 
Figure 61. A representation of PARP roles in cell physiology. DNA damage caused by ischemia, 
excitotoxicity, oxidative stress, inflammation or toxins leads to PARP-1 activation. Niconimide 
adenine dinucelotide (NAD+) is required during PARP-1 activation and as a result, ADP-riboses 
is generated around accessory proteins including histone and PARP-1. Simultaneously, poly 
(ADP-ribose) glycohydrolase (PARG) degrades poly (ADP-riboses). DNA repair mechanism and 
enabling DNA accessibility are activated by moderate DNA damage to facilitate DNA repair. 
However, severe DNA damage stimulates the over-activation of PARP which may deplete the 
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stores of cellular energy leading to cell death. PARP can also enhance inflammatory responses 
by acting as a co-activator of nuclear factor kappa B (NF-κB), which is a central transcription 
factor for pro-inflammatory genes (TM., 2007). 
 
Due to its role in NF-κB driven expression of inflammatory mediators by glia during the 
neuroimmune response, PARP-1 is involved in the pathogenesis of neurodegenerative 
disorders, where is excessive release of pro-inflammatory products by activated glia 
causes neurotoxicity. Such neurodegenerative disorders include Parkinson’s disease 
(PD) where there is an abundance of PARP-containing nuclei in the dopaminergic 
neurons of the substantia nigra (Infante et al., 2007, Chiarugi et al., 2003). PARP-1 is 
also involved in another neurodegenerative disease, which is Alzheimers disease (AD). 
Increased levels of peripheral blood mononucleaar cells (PBMCs) expressing 
proinflammatory proapoptotic PARP-1 where found in AD patients (Kassner et al., 
2008). PARP-1 plays a role in autoimmune CNS injury such as multiple sclerosis, which 
is an inflammatory disorder of the brain and spinal cord in which focal lymphocytic 
infiltration leads to damage of myelin and axons (Compston et al., 2008). In a mouse 
model of multiple sclerosis, PARP-1 knockout showed a decrease in the severity of the 
disease outcome (Krishnakumar et al, 2010). It also has been reported that cells lacking 
PARP-1 are more susceptible to apoptosis induced by DNA-damaging agents that 
activate the base excision repair pathway compared to normal cells (Oliver et al., 1999). 
It is evident that PARP-1 is an important element in neuronal death pathways initiated 
by experimental stroke and in N-methyl-D-aspartate (NMDA), nitric oxide, and 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxicity (Goto et al, 2002). MPTP is a 
neurotoxin that causes Parkinsonism, and it has benefited in revealing greater 
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information about the pathogenesis of Parkinson's disease. In a study, mice lacking the 
gene for PARP showed higher reduction in MPTP neurotoxicity compared to wild type 
mice. The study concluded that PARP activation plays a critical role in MPTP-induced 
Parkinsonism and suggested that inhibitors of PARP may have protective benefit in the 
treatment of Parkinson's disease (Mandir et al., 1999). Moreover, Nitric oxide (NO) and 
peroxynitrite, generated from NO and superoxide anion, have been implicated as 
mediators of neuronal damage following focal ischemia. In a study PARP-1 knockout 
showed a significant increase in protection against glutamate-NO-mediated ischemic 
insults in vitro and major decreases in infarct volume after reversible middle cerebral 
artery occlusion (Eliasson et al., 1997). 
In addition, caspase-3 was also essential for apoptosis-associated proteolysis of 14 
caspase substrates as well as nuclear collapse, chromatin margination, and DNA 
fragmentation (Slee et al., 2001). During drug-induced apoptosis in a variety of cells, 
PARP is cleaved into 89-kDa fragment that contain the active site and 24-kDa 
fragments that contain the DNA-binding domain of the enzyme. Such cleavage 
essentially inactivates the enzyme by destroying its ability to respond to DNA strand 
breaks (Boulares et al., 1999). Moreover, by using poly (ADP-ribosyl)ation, PARP-1 has 
the ability to modify a variety of chromatin proteins, including histones, and thereby 
dramatically alter chromatin structure (Kraus et al., 2003). In this study, cells expressed 
caspase 3 and cleaved 89-kDa PARP when exposed to hypoxia which is demonstrated 
in Western blotting results. Treatment with 10 μM citicoline showed 88% reduction of 
cleaved PARP expression and 86% inhibition of active caspase-3 expression. These 
results shows for the first time that citicoline is protective against cell death in stroke 
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mimicking conditions by inhibiting caspase 3 cleavage of PARP. To confirm results from 
Western blotting, indirect immunofluorescence was used to investigate the effect of 
citicoline on caspase 3 and H2B Ser14 activity in hypoxia treated cells. The cells were 
incubated for 24 hours in hypoxia conditions with or without different citicoline 
concentrations. After fixation, the cells were stained using anti-active caspase 3 or H2B 
Ser14 with the nuclei counterstained with DAPI. The results were consistent with 
Western blotting results by showing citicoline at 10 μM concentration as the optimum 
concentration for caspase 3 and H2B Ser14 inhibition. Citicoline at 10 μM concentration 
showed an inhibition of 70% in H2B Ser14 expression and an inhibition of 72% in active 
caspase 3 expression. Cells incubated in normoxia conditions showed no activation of 
caspase 3 and H2B Ser14. 
In this study human apoptosis RT² profiler PCR array, which profiles the expression of 
84 key genes involved in programmed cell death, was used to determine the effect of 
citicoline on the expression of these genes in hypoxia. This array includes TNF ligands 
and their receptors, members of the bcl-2, caspase, IAP, TRAF, CARD, death domain, 
death effector domain, and CIDE families, as well as genes involved in the p53 and 
DNA damage pathways. Cells were seeded into 2×T75 flasks to obtain sufficient RNA 
concentration for this experiment. The optimum citicoline concentration was determined 
to be 10 μM, and therefore cells in one T75 flask were treated with 10 μM citicoline and 
the second flask was used for control (untreated) cells. Both flasks were incubated for 
24 hours in hypoxia before performing RNA extraction and real time PCR. 
The results showed a significant decrease in caspase 8 expression in cells treated with 
10 μM citicoline compared to control cells. Caspase-9 is synthesized as 46 kDa 
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precursor protein that is implicated in apoptosis. Caspase-8 is a member of the cysteine 
proteases, which are associated in apoptosis and cytokine modulation. Caspase-8 is 
produced as an inactive single polypeptide chain zymogen procaspase and is activated 
by proteolytic cleavage. Caspase-8 is known to propagate the apoptotic signal either 
through the intrinsic or the extrinsic apoptotic pathway. In the extrinsic pathway, 
caspase 8 cleaves the BH3 Bcl2-interacting protein, which leads to the release of 
cytochrome c from mitochondria. Cytochrome c then binds with Apaf-1, the mammalian 
Ced-4 homologue, together with dATP. The resultant complex recruits Caspase-9 
leading to its activation. Activated Caspase-9 cleaves downstream caspases such as 
Caspase-3, -6 and -7 initiating the caspase cascade. In the extrinsic apoptotic pathway, 
activation of death receptors through bindings of ligands leads to FADD and caspase 8 
recruitment, which activates caspase 8. Activation of caspase 8 directly activates 
capase 3 leading to apoptosis (Kruidering et al., 2000, Oberst et al., 2010, Kuida et al., 
2000). In this study, and for the first time, citicoline is shown to be protective against 
hypoxia induced cell death by inhibiting the expression of caspase 9 and caspase 8. 
The results from PCR array displayed a significant decrease in BNIP3 expression in 
cells treated with 10 μM citicoline. BNIP3 (Bcl-2/adenovirus E1B 19-kDa interacting 
protein 3) is a proapoptotic protein that contains a single Bcl-2 homology 3 (BH3) 
domain and is classified in the BH3-only subfamily of Bcl-2 proteins (Zhang et al., 
2009). BNIP3 plays a role in hypoxia-mediated cell death by causing mitochondrial 
dysfunction via activation of Bax or Bak, which leads to mitochondrial fragmentation and 
release of cytochrome c (Kubli et al., 2007). Bnip3L is a proapoptotic member of the 
Bcl-2 family that induces cell death, and plays an essential role in cardiac cell death 
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during hypoxia. Bnip3L is activated by hypoxia-inducible factor 1 (HIF-1) in response to 
hypoxia (Fei et al., 2004). In a study, inhibiting of HIF-1α or Bnip-3L with small 
interfering RNA (siRNA) completely blocked the hypoxia-induced apoptosis and Bnip3L 
expression (Krick et al., 2005). Caspase 4 belongs to inflammatory caspases, which 
contain a long prodomain with a caspase recruitment domain (CARD). It can be 
activated by danger or stress signals, such as UV irradiation, or molecules released 
from injured cells, such as uric acid crystals, which are collectively called danger-
associated molecular patterns, induce an inflammatory response mediated by 
inflammasomes (Sollberger et al., 2012). The results from this study shows an inhibitory 
effect of citicoline on caspase 4 expression. 
Caspase-4 is localized to the ER membrane and is primarily activated in ER stress-
induced apoptosis. Ischemia can cause neuronal damage, which is related to stress 
acting on the ER, leading to intraluminal accumulation of unfolded proteins. ER stress 
induces three major cellular responses: unfolded protein response (UPR), ER-
associated degradation, and apoptosis. Excessive or long-termed ER stress results in 
apoptotic cell death, involving nuclear fragmentation, condensation of chromatin, and 
shrinkage of the cell body. Reduction of caspase-4 expression decreases ER stress-
induced apoptosis (Hitomi et al., 2004). 
In this study, citicoline was found to reduce the expression of protein cell death-
inducing DFFA-like effector B (CIDEB). CIDEB mediates lipid droplet (LD) fusion, as 
well as very-low-density lipoprotein (VLDL) maturation (Singaravelu et al., 2013). It 
contains an N-terminal CIDE-N domain that shares sequence similarity to the N-terminal 
CAD domain (NCD) of DNA fragmentation factors Dffa/Dff45/ICAD and Dffb/Dff40/CAD 
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(Wu et al., 2008). CIDE-B protein is localized in mitochondria and forms homodimers 
and heterodimers with other family members. By localizing to mitochondria, CIDE-B 
may interact directly with Bcl-2 family proteins such as Bcl-2 and Bcl-XL to chelate anti-
apoptotic proteins, thereby inducing apoptosis. CIDE-B could also directly cause 
mitochondria alteration such as disruption of mitochondria membrane potential, 
induction of the production of reactive oxygen species, and the release of apoptosis-
inducing factors (Chen, 2000). DNA fragmentation factor subunit alpha (DFFA) is a 
caspase-3 substrate that must be cleaved before apoptotic internucleosomal DNA 
fragmentation can proceed. DFFA (45 kDa) exists as complex with DFFB (40 kDa) to 
form DFF. DFF is a cytosolic factor, which is required for the initiation of endonuclease-
mediated DNA fragmentation and can be directly activated by caspase-3 in vitro. 
Therefore, DFF serves as a component in the executioner phase of apoptosis (Granville 
et al., 1998, Wolf et al., 1999). 
Lymphotoxin-β receptor (LTBR)1 is a member of the tumour necrosis factor receptor 
(TNFR) superfamily and is ubiquitously expressed on the surface of most cell types, 
except T and B lymphocytes. Membrane anchored lymphotoxin (LT) a1b2 and LIGHT 
(homologous to LT, inducible expression, competes with herpes simplex virus (HSV) 
glycoprotein D for HSV entry mediator (HVEM), a receptor expressed on T 
lymphocytes), both members of the TNF superfamily, are functional ligands for the LTb 
receptor (LTBR). LIGHT is able to induce cell death via the non-death domain 
containing receptor LTBR to activate both caspase-dependent and caspase-
independent pathway (Chen et al., 2003, Wimmer et al., 2012). From the microarray 
results, it was found to be reduced by citicoline treatment. Ligand-induced activation of 
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LTBR triggers the formation of receptor-associated cytoplasmic signalling complexes 
containing TNFR-associated factors (TRAFs) that regulate interactions of the receptor 
with downstream kinases. TRAF3 has been shown to mediate activation of JNK and 
induction of cell death by LTBR (Bista et al., 2010). 
In this study, the expression of tumor necrosis factor receptor type 1-associated 
DEATH domain protein (TRADD) was found to be reduced by citicoline. TRADD is an 
adapter molecule that contains an N-terminal TRAF binding domain and a C-terminal 
death domain along with nuclear import and export sequences that function as a 
transport system between the cytoplasm and nucleus. It links the interaction between 
tumor necrosis factor receptor-1 (TNFR-1) and receptor-interacting serine/threonine-
protein kinase 1 (RIP1). The death domain of TRADD contains the nuclear import 
sequence and expression of the core death domain (nuclear TRADD) causes a special 
nuclear localization and activation of a distinct apoptotic pathway. Activation of TNFR-1 
by binding of ligand leads to TRADD recruitment, which then recruit and activate the 
initiator caspase, caspase-8, and ultimately result in effector caspase activation, and 
apoptosis (Bender et al., 2005, Park et al, 2014). 
Tumour protein p53 binding protein 2 (TP53BP2) is a gene that encodes two 
proteins apoptosis-stimulating of p53 protein 2 (ASPP2) and tumour suppressor p53-
binding protein 2 (p53BP2) (Takahashi et al., 2004). ASPP2 changes the promoter 
specificity of p53 by increasing the DNA binding and transactivation of p53 on the pro-
apoptotic genes such BAX which induces apoptosis (Sun et al., 2008). Blocking 
endogenous ASPP expression inhibits the apoptotic function of endogenous p53 in 
response to apoptotic stimuli (Samuels-Lev et al., 2001). 53BP2 interaction with p53, 
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mediates some of p53 functions such as apoptosis induction and cell cycle arrest and 
overexpression of 53BP2 was found to induce apoptosis (Mori et al., 2000, Yang et al., 
1999). TNF receptor superfamily 25 (TNFRSF25) is a member of the TNF-receptor 
family with a typical death domain. TNFRSF25 induces NF-κB and promotes cell 
survival signals via TRADD and TRAF2 (Fang et al., 2008). TRAF2 activation induces 
NF-κB expression, which in turn inhibits apoptosis by supressing caspase 8 (Wang et 
al., 1998). Nucleotide-binding oligomerization domain-containing protein 1(NOD1) is 
one of the most prominent members of the NLR (NOD-LRR) family -proteins. Upon 
activation, NOD1 initiates signal transduction mechanisms that include stimulation of 
NF-κB through receptor-interacting serine/threonine-protein kinase 2 (RIP2) binding to 
IAPs (Correa et al., 2012). The neuronal apoptosis inhibitory protein (NAIP) is a 
member of human inhibitors of apoptosis IAP family that is characterized by highly 
conserved N-terminal motifs called baculovirus inhibitor of apoptosis repeats (BIR). The 
BIR domains of NAIP are potent inhibitors of caspase 3 (Maier et al., 2002). Over-
expression of NAIP has demonstrated protective properties against apoptosis induced 
by a variety of signals in vitro (Perrelet et al., 2000). 
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Conclusion. 
 
Stroke is caused by focal cerebral ischemia resulting from occlusion of a cerebral blood 
vessel, usually an artery. Regardless of ischemia severity, collateral circulation may 
develop by enlargement of pre-existing anastomotic channels or angiogenesis (DA et 
al., 1998). Angiogenesis induction stimulates endogenous recovery mechanisms such 
as neurogenesis, synaptogenesis, and neuronal and synaptic plasticity. These 
mechanisms are all associated with long-term repair and restoration process of the 
brain after an ischemic event (Ergul et al., 2012). Citicoline is a neuroprotectant and 
neurorestorative agent that is used as a trial treatment of acute ischemic stroke 
(Dávalos et al., 2011). It increases the neuronal plasticity within non-injured and 
functionally connected brain regions as well as to promote functional recovery (Hurtado 
et al., 2007). However, the exact the molecular mechanisms in which citicoline acts is 
not fully understood. Therefore, this project investigates the roles and mechanisms 
through which citicoline induce in vitro angiogenesis (EC proliferation, migration, and 
tube formation) which lead to several important and novel findings. The proliferation 
assay showed that citicoline presented no mitogenic or chemotactic on hCMEC/D3 
proliferation. However, citicoline significantly increased cell migration and tube formation 
in Matrigel™ . The results from Kinexus analysis showed an up-regulation of Her-2 
expression by citicoline. This finding was supported by Western blotting results. 
Citicoline was found to increase Her-2 expression in hCMEC/D3, and therefore, 
citicoline stimulation of angiogenesis through Her-2 phosphorylation was further 
examined using Her-2 inhibitor. Inhibition of Her-2 blocked the angiogenic effect of 
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citicoline by inhibiting Erk1/2 expression and tube formation in Matrigel™ , which 
suggests that citicoline induce hCMEC/D3 angiogenesis through Her-2 pathway. 
Citicoline has also shown protective effects against apoptotic processes after stroke 
(Sahin et al., 2010). The Kinexus results revealed that citicoline significantly down-
regulated the expression of Histone H2B Ser14 in HCMEC/D3. H2B phosphorylation at 
serine 14 (Ser14) has been linked to chromatin condensation during apoptosis (Lu et 
al., 2010). Citicoline suppression of H2B Ser14 expression was supported by Western 
blotting, and immunofluorescence results confirming the protective effect of citicoline 
against apoptosis through H2B Ser 14 inhibition. Another marker of apoptosis (caspase-
3) was examined using Western blotting and immunofluorescence. Caspase-3 is 
required neuromas typical hallmarks of apoptosis, and is essential for apoptotic 
chromatin condensation and DNA fragmentation in numbers of cell types (Porter et al., 
1999). Western blotting and immunofluorescence results demonstrated a significant 
inhibition of caspase-3 activity by citicoline, which further provides accumulative 
evidences of the protective effects of citicoline against apoptosis. Cleaved caspase-3 
and cleaved PARP expression parallels apoptosis (Puig et al., 2001). Results from 
Western blotting showed inhibitory effect of citicoline against PARP expression, which 
revealed more information about the pathway in which citicoline acts as an antiapoptotic 
agent. However, results from detecting apoptosis using flow cytometry showed a level 
of inconsistency which could be improved using an alternative protocol. In this study P.I 
staining was used to detect apoptotic cells under the fluorescence microscope. Cells 
were considered apoptotic when displayed signs of apoptosis such as nuclear 
condensation, fragmentation, uptake of PI stain (red colour) into the nucleus, disruption 
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of cell cytoplasm and shrinkage of the cells. The normal cells appeared swollen with 
round clear blue nuclei. The results displayed a protective effect of citicoline on 
hCMEC/D3 against apoptosis induced by hypoxia. The Human Apoptosis RT² Profiler 
PCR Array was used to detect the effect of citicoline on the expression of 84 key genes 
involved in programmed cell death. The results showed a significant inhibition of 
citicoline against several pro-apoptotic genes including BNIP3, BNIP3L, caspase 4, 
caspase 8, caspase 9, CIDEB, DFFA, LTBR, TP53BP2, TRADD, and TRAF3. They also 
show a significant stimulatory effect of citicoline on the expression a number of anti-
apoptotic genes including NAIP, NOD1, TNFRSF25, and TP53. 
Figure 62. Proposed apoptotic pathway in which citicoline acts. 
 
161 | P a g e  
 
Further Work. 
This study demonstrated the role of citicoline in modulation of angiogenesis using in 
vitro angiogenesis assays. However, there is a need for a confirmation of these results 
to establish windows of opportunity to greatly increase the potential of citicoline in stroke 
therapy. Therefore, it is worthwhile to use vivo assays such as middle cerebral artery 
occlusion (MCAO) rat model to demonstrate citicoline effect as a pro-angiogenic agent. 
It would also be useful to investigate the same apoptotic and angiogenic pathways 
explored in this study in vivo, and use immunohistochemical staining to detect the 
expression of the key proteins involved.   
Although the present study demonstrated citicoline up-regulation and down-regulation of 
the genes involved in the apoptotic pathway, there is a need for confirmation of these 
genes by Western blotting, for a better understanding of the underlying molecular 
mechanisms by which citicoline is responsible for the modulation of cell survival. 
The results from flow cytometry showed a level of inconsistency across all conditions, 
which could be due to false positive events associated with PI staining of RNA within 
the cytoplasmic compartment. Therefore, it would be advisable to modify the 
conventional Annexin V-FITC Apoptosis protocol by adding RNase for cytoplasmic RNA 
removal. 
In the therapeutic process of acute ischemic stroke, the effectiveness of drug delivery is 
very important. Therefore, it would be interesting to investigate different in vivo drug 
delivery systems to find the optimum method of delivering citicoline to the target tissue. 
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Appendices.  
Appendix 1. 
Reagents. 
 Acrylamide/Bis solution (Bio-Rad Laboratories). 
 Alexa Fluor® Goat Anti-Rabbit (Life Technologies, UK). 
Ammonium persulphate (Sigma, UK). 
Annexin V-FITC Apoptosis Detection Kit (Sigma, UK). 
Anti-Caspase 3, Active antibody produced in rabbit polyclonal (Sigma, UK). 
Anti-Caspase 3 antibody produced in rabbit (Sigma, UK). 
Anti-Cleaved PARP antibody rabbit polyclonal (abcam). 
Anti-ErbB2/Her-2, clone EP1045Y, Rabbit Monoclonal Antibody (Abcam, UK). 
Anti-ERK1/2 (K-23) rabbit monoclonal IgG antibody (Santa Cruz Biotechnology). 
Anti-Histone H2B rabbit polyclonal antibody (Millipore, USA). 
Anti-PARP rabbit polyclonal antibody (abcam). 
Anti-phospho-erbB2 (Y1221), clone 7F8 rabbit monoclonal (Abcam, UK). 
Anti-Phospho-Erk1/2 (E-4) mouse monoclonal antibody (Santa Cruz Biotechnology). 
Anti-phospho-Histone H2B (Ser14) Polyclonal Antibody (Millipore, USA). 
BD Matrigel™ ™ Basement Membrane Matrix (BD Biosciences, UK) 
Bio-Rad protein assay kit (Bio-Rad Laboratories, Germany). 
Bis (N,N‟-methylenebisacrylamide), (Sigma, UK). 
BLUeye Prestained Protein Ladder (Geneflow, UK). 
Bovine serum albumin, BSA (Sigma, UK). 
Bromophenol blue (Serva). 
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Citicoline (Ferrer, Spain). 
Coomassie brilliant blue (BDH, UK). 
DMSO, Dimethyl sulfoxide (Sigma, UK). 
Endothelial Basal Meduim-2, EBM-2 (Lonza, USA). 
ErbB-2 inhibitor GW2974 (Sigma, UK). 
Ethanol (Fisher Scientific International, UK). 
EZ-ECL chemiluminensence detection kit for HRP (Biological industries, Israel) 
Fibroblast growth factor-2 (R&d System, UK). 
Foetal Bovine Serum, FBS (Lonza, USA). 
Giemsa stain (Sigma, UK). 
Glycerol (BDH,UK). 
Glycine (BDH,UK). 
Hoescht stain solution (H6024) (Sigma, UK). 
Hydrochloric acid (BDH, UK). 
Hypoxia gas (Boc Gases, UK) 
Isopropanol (Sigma, UK). 
Methanol (Fisher Scientific International) 
Milk (Local store, UK) 
N,N,N‟,N‟- tetramethylethylenediamine (TEMED)( Sigma, UK). 
Normal Goat Serum (10%) (Life Technologies, UK). 
Paraformaldehyde, PFA (General Purpose Reagent, UK). 
Phosphate Buffer Saline, PBS (Lonza, USA). 
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Polyclonal Goat Anti-rabbit Immunoglobulin/Horseradish peroxidase, HRP (Dako, 
Denmark) 
Polyclonal Rabbit Anti-goat Immunoglobulin /Horseradish peroxidase, HRP (Dako, 
Denmark). 
Poly-L-lysine solution 0.1 % (w/v) in H2O (Sigma, UK). 
Propidium iodide,PI (Sigma Aldrich, USA). 
RNase-Free DNase Set (Qiagen, UK). 
RNeasy Mini Kit (Qiagen, UK). 
RT² First Strand Kit (Qiagen, UK). 
RT² SYBR Green qPCR Master Mixes (Qiagen, UK). 
Sodium chloride (Sigma, UK). 
Sodium Dodecyl Sulphate,SDS (BDH, UK). 
Sodium hydroxide (BDH, UK). 
Staurosporine solution from Streptomyces sp1 mM in DMSO (Sigma Aldrich,USA). 
Tris (hydroxylmethyl) methylamine (BDH, UK) 
Trizam@ base, minimum 99.9% titration (Sigma,USA) 
Trypsin10X (Sigma, UK) 
Tween-20 (Sigma, UK). 
VECTASHIELD Mounting Medium with DAPI (Vector Laboratories, UK). 
Virkon disinfectant (Antec Internationa). 
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Appendix 2.  
Preparation of the Kinexus buffer. 
  
1. 20 mM MOPS, pH 7.0 (any other buffer without Tris at this pH could be substituted).  
2. 2 mM EGTA (to bind calcium).  
3. 5 mM EDTA (to bind magnesium and manganese).  
4. 30 mM sodium fluoride (to inhibit protein-serine phosphatases).  
5. 60 mM glycerophosphate, pH 7.2 (to inhibit protein-serine phosphatases). 6. 20 mM 
sodium pyrophosphate (to inhibit protein-serine phosphatases).  
7. 1 mM sodium orthovanadate (to inhibit protein-tyrosine phosphatases).  
8. 1 mM phenylmethylsulfonylfluoride (to inhibit proteases).  
9. 3 mM benzamidine (to inhibit proteases).  
10. 5 μM pepstatin A (to inhibit proteases).  
11. 10 μM leupeptin (to inhibit proteases).  
12. 1% Triton X-100 (can be substituted with 1% Nonidet P-40).  
 Important Note: Do not add if you intend to first prepare a cytosolic fraction; 13. 1 
mM dithiothreitol (To disrupt disulfate bonds).  
 Important Note: Dithiothreitol must be added to lysis buffer immediately before 
use.  
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Appendix 3. 
List of figures.   
Figure 1. Citicoline Structure.  
Figure 2. The CDP-choline pathway.  
Figure 3. The points where citicoline has been reported to have a pharmacologic effect 
in the ischemic cascade are marked in red.  
Figure 4. A representation of the two major types of stroke.  
Figure 5. Angioblasts in the embryo accumulate during the process of vasculogenesis, 
and expands and remodels in angiogenesis.  
Figure 6. The scanning electron micrograph displays pericytes wrapping their processes 
around a small blood vessel in the mammary gland of a cat.  
Figure 7. A representation of the BBB. It is formed by capillary endothelial cells, 
embedded in basal lamina and surrounded by astrocytic perivascular endfeet.  
Figure 8. A representation of different in vitro cell-based blood–brain barrier (BBB) 
models.  
Figure 9. Signalling pathways for cell migration regulated Erk.  
Figure 10. A representation of the two major apoptotic pathways; the extrinsic and the 
intrinsic pathway.  
Figure 11. Standard curve for protein amount estimation in μg. 
Figure 12. The Kinexus antibody microarray screen performed by Kinexus on BAEC  
Figure 13. Chemical structure of GW2974 (Kamlesh Sodani, 2012). 
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Figure 14. Representative western blot showing HER2 expression in cells untreated and 
treated with different concentrations of citicoline (1 µM, 5 µM and 10 µM). 
Figure 15. . Representative western blot showing pilot experiment to determine optimal 
HER2 inhibitor concentration. 
Figure 16. Representative western blot showing 25 ng FGF-2 and 10 µM citicoline effect 
on pErk expression with and without 5 µM HER2 inhibitor.   
Figure 17. Citicoline (10 μM) significantly increased the formation of tube-like structures 
of HCMEC/D3 with a stronger effect than fibroblast growth factor-2 (FGF-2). 
Figure 18. Representative examples of the effect of citicoline on tube formation with or 
without Her-2 inhibitor in comparison to FGF-2, FGF-2 + Her-2 inhibitor, and control 
cells. 
Figure 19. Pro-angiogenic effects of citicoline and FGF-2 on hCMEC/D3 tube formation. 
Figure 20. A) Control (untreated) cells in hypoxia. B) 1 μM citicoline treated cells in 
hypoxia. C) 5 μM citicoline treated cells in hypoxia. D) 10 μM citicoline treated cells in 
hypoxia. 
Figure 21. Pro-angiogenic effects of citicoline on hCMEC/D3 cell migration. 
Figure 22. A) Control untreated cells in hypoxia. B) 1μM citicoline treated cells in 
hypoxia. C) 5μM citicoline treated cells in hypoxia. D) 10 μM citicoline treated cells in 
hypoxia. 
Figure 23. Quantitative analysis of the apoptotic cells in percentage. Cells treated with 
different concentrations of citicoline (1 μM, 5 μMm, 10 μM) in hypoxia conditions. 
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Figure 24. A) Control untreated cells in normoxia. B) 1µM citicoline treated cells in 
normoxia. C) 5 µM citicoline treated cells in normoxia. D) 10 µM citicoline treated cells in 
normoxia. 
Figure 25. Representative Western blot showing the effect of citicoline on PARP 
expression in normoxia and hypoxia. 
Figure 26. Representative Western blot showing showing the effect of citicoline on 
caspase 3 expression in normoxia and hypoxia. 
Figure 27. Apoptotic stimulation activates caspases which in turn activates Mst1. Mst1 
is activated by caspases upon exposure to apoptotic stimuli. 
Figure 28. Representative Western blot showing the effect of citicoline on H2B 
expression in normoxia and hypoxia. 
Figure 29. Active caspase-3 expression in cells treated with different concentrations of 
citicoline (1 μM, 5 μMm, 10 μM) in hypoxia conditions. 
Figure 30. Control (untreated) cells in hypoxia. 
Figure 31.1 µM citicoline treated cells in hypoxia conditions. 
Figure 32. 5 µM citicoline treated cells in hypoxia conditions. 
Figure 33. 10 µM citicoline treated cells in hypoxia conditions. 
Figure 34. Control cells in normoxia conditions. 
Figure 35. 1 µM citicoline treated cells in normoxia conditions. 
Figure 36. 5 µM citicoline treated cells in normoxia conditions. 
Figure 37. 10 µM citicoline treated cells in normoxia conditions. 
Figure 38. H2B Ser14 expression in cells treated with different concentrations of 
citicoline (1 μM, 5 μMm, 10 μM) in hypoxia conditions. 
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Figure 39. Control cells in hypoxia conditions. 
Figure 40. 1 µM citicoline treated cells in hypoxia conditions. 
Figure 41. 5 µM citicoline treated cells in hypoxia conditions. 
Figure 42. 10 µM citicoline treated cells in hypoxia conditions. 
Figure 43. Control cells in normoxia. 
Figure 44. 1 µM citicoline treated cells in normoxia conditions. 
Figure 45. 5 µM citicoline treated cells in normoxia conditions. 
Figure 46. 10 µM citicoline treated cells in normoxia conditions 
Figure 47. Percentage of late apoptotic cells treated with different concentrations of 
citicoline (1μM, 5 μM and 10 μM) in hypoxia and normoxia conditions. 
Figure 48. Percentage of early apoptotic cells treated with different concentrations of 
citicoline (1μM, 5 μM and 10 μM) in hypoxia and normoxia conditions. 
Figure 49. Flow charts of control cells in hypoxia conditions. 
Figure 50. 1 μM citicoline treated cells in hypoxia conditions. 
Figure 51. 5 μM citicoline treated cells in hypoxia conditions. 
Figure 52. 10 μM citicoline treated cells in hypoxia conditions. 
Figure 53. Control cells in normoxia conditions. 
Figure 54. 1 μM citicoline treated cells in normoxia conditions. 
Figure 55. 5 μM citicoline treated cells in normoxia conditions. 
Figure 56. 10 μM citicoline treated cells in normoxia conditions. 
Figure 57. Relative gene expression between control cells and cells treated with 10 μM 
citicoline was calculated using qRT-PCR (GAPDH, HPRT1 and RPLPO were taken as 
endogenous control). 
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Figure 58. Proposed pathway of citicoline induced ERK1/2 expression. 
Figure 59. The PI3K/Akt signalling pathway. Phosphorylation of Akt phosphorylates 
BAD and a non-active form of caspase-9. 
Figure 60. Ischemic cascade leading to cerebral damage. 
Figure 61. A representation of PARP roles in cell physiology. DNA damage caused by 
ischemia, excitotoxicity, oxidative stress, inflammation or toxins leads to PARP-1 
activation. 
Figure 62. Proposed apoptotic pathway in which citicoline acts. 
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Appendix 4. 
List of tables. 
Table 1. Examples of how Matrigel™ promotes differentiation in different cell types. 
Table 2. The volume of BSA, dH2O and Bio-Rad required to establish the standard 
curve. 
Table 3. Preparation of separating gel. 
Table 4. Preparation of stacking gel. 
Table 5. The real-time cycler settings. 
Table 6. The effects of citicoline on hCMEC/D3 cells proliferation. 
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Appendix 5. 
PCR data. 
Untreated Sample. 
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Treated Sample.  
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Gene Treated Untreated  Both BNIP3 -10.6 
BRAF V-raf murine sarcoma viral oncogene homolog B1 x     BNIP3L -2.6 
CFLAR CASP8 and FADD-like apoptosis regulator x     CASP4 -2.6 
CYCS Cytochrome c, somatic x     CASP8 -1.1 
FADD Fas (TNFRSF6)-associated via death domain x     Caspase 9 -52 
IGF1R Insulin-like growth factor 1 receptor x     CIDEB -3.3 
Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 x     DFFA -2.14 
PYCARD PYD and CARD domain containing x     LTBR -1.07 
TRAF2 TNF receptor-associated factor 2 x     NAIP 1 
BIRC6 Baculoviral IAP repeat containing 6   x   NOD1 2.46 
BNIP2 BCL2/adenovirus E1B 19kDa interacting protein 2   x   TNFRSF25 7 
CASP10 Caspase 10, apoptosis-related cysteine peptidase   x   TP53 11.3 
CASP6 Caspase 6, apoptosis-related cysteine peptidase   x   TP53BP2 -1.2 
CASP7 Caspase 7, apoptosis-related cysteine peptidase   x   TRADD -3.7 
CRADD CASP2 and RIPK1 domain containing adaptor with death 
domain   x   TRAF3 -1.9 
FAS Fas (TNF receptor superfamily, member 6)   x     
MCL1 Myeloid cell leukemia sequence 1 (BCL2-related)   x     
RIPK2 Receptor-interacting serine-threonine kinase 2   x     
TNFRSF11B Tumor necrosis factor receptor superfamily, member 
11b   x     
TNFRSF9 Tumor necrosis factor receptor superfamily, member 9   x     
XIAP X-linked inhibitor of apoptosis   x     
BCL2L1 BCL2-like 1     x   
BNIP3 BCL2/adenovirus E1B 19kDa interacting protein 3     x   
BNIP3L BCL2/adenovirus E1B 19kDa interacting protein 3-like     x   
CASP4 Caspase 4, apoptosis-related cysteine peptidase     x   
CASP8 Caspase 8, apoptosis-related cysteine peptidase     x   
Caspase 9, apoptosis-related cysteine peptidase     x   
CIDEB Cell death-inducing DFFA-like effector b     x   
DFFA DNA fragmentation factor, 45kDa, alpha polypeptide     x   
LTBR Lymphotoxin beta receptor (TNFR superfamily, member 3)     x   
NAIP NLR family, apoptosis inhibitory protein     x   
NOD1 Nucleotide-binding oligomerization domain containing 1     x   
TNFRSF25 Tumor necrosis factor receptor superfamily, member 25     x   
TP53 Tumor protein p53     x   
TP53BP2 Tumor protein p53 binding protein, 2     x   
TRADD TNFRSF1A-associated via death domain     x   
TRAF3 TNF receptor-associated factor 3     x   
198 | P a g e  
 
Appendix 6.  
 
Protein Estimation. 
 
 
Caspase 3 + H2B 
 
0.05  0.1  0.2  0.3  0.4  0.5  
0.44  0.613  0.77  0.93  1  1.18  
0.46  0.53  0.79  0.85  1  1.1  
0.01  0.1  0.2  0.3  0.4  0.5  
0.45  0.5715  0.78  0.89  1  1.14  
 
Normoxia 
 
C  10  5  1  
0.847  0.88  0.911  0.79  
0.69  0.788  0.88  0.73  
0.7685  0.834  0.8955  0.76  
 
Hypoxia 
 
C  10  5  1  
0.816  0.77  0.799  0.873  
0.74  0.78  1.71  1.295  
0.778  0.775  1.2545  1.084  
 
Amount of Protein in (μg in 2μl) Normoxia Samples 
 
C 10 5 1 
0.204011 0.249308 0.29184 0.198133 
 
Amount of Protein in (μg in 2μl) Hypoxia Samples 
 
C 10 5 1 
0.210581  0.208506  0.540111  0.422199  
 
Amount of Protein in Normoxia Samples μg/μl 
 
C 10 5 1 
1.020055  1.246542  1.459198  0.990664  
 
Amount of Protein in Hypoxia μg/μl Samples 
 
C 10 5 1 
1.052905  1.042531  2.700553  2.110996  
 
 
Amount of Protein in 20 μl Normoxia 
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C 10 5 1 
20.40111  24.93084  29.18396  19.81328  
 
Amount of Protein in 20 μl Hypoxia 
 
C 10 5 1 
21.05809  20.85062  54.01107  42.21992  
 
 
Loading Volume Normoxia 
 
C 10 5 1 
19.60678 16.04438 13.70616 20.18848 
 
Loading Volume Hypoxia 
 
C 10 5 1 
18.99507 19.18408 7.40589 9.474201 
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PARP + Active PARP 
0.01  0.1  0.2  0.3  0.4  0.5  
0.5  0.613  0.783  0.95  1.054  1.152  
0.468  0.603  0.774  0.913  0.978  1.261  
0.01  0.1  0.2  0.3  0.4  0.5  
0.484  0.608  0.7785  0.9315  1.016  1.2065  
 
Normoxia 
C  10  5  1  
1.9  1.5  1.892  1.7  
1.027  1.7  0.974  1.51  
1.4635  1.6  1.433  1.605  
 
Hypoxia 
C  10  5  1  
1.45  1.098  1.61  1.35  
1.5  1.7  1.55  1.7  
1.475  1.399  1.58  1.525  
 
Amount of Protein in (μg in 2μl) Normoxia Samples 
C  10  5  1  
0.684647  0.779046  0.663555  0.782503  
 
Amount of Protein in (μg in 2μl)  Hypoxia Samples  
 
C  10  5  1  
0.6926  0.640041  0.765214  0.727178  
 
Amount of Protein in Normoxia Samples μg/μl 
C  10  5  1  
3.423237  3.895228  3.317773  3.912517  
 
Amount of Protein in Hypoxia μg/μl Samples 
C  10  5  1  
3.463001  3.200207  3.826072  3.635892  
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Amount of Protein in 20 μl Normoxia 
C  10  5  1  
68.46473  77.90456  66.35546  78.25035  
 
Amount of Protein in 20 μl Hypoxia 
C  10  5  1  
69.26003  64.00415  76.52144  72.71784  
 
Loading Volume Normoxia 
C  10  5  1  
11.68485  10.26897  12.05628  10.2236  
 
Loading Volume Hypoxia 
C  10  5  1  
11.55067  12.49919  10.45459  11.00143  
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BSA 
(mg) O.D. 570 nm  Mean    
0 0 0 0  
BSA 
(mg) Mean 
10 0.160 0.1 0.13  0 0 
20 0.118 0.027 0.0725  10 0.0875 
40 0.197 0.152 0.1745  20 0.1505 
     40 0.268 
 
    
control  10 μM Citicoline  10 μM Citicoline 
+ 5μM Her-2 
inhibitor  
FGF-2  FGF-2 + 5μM 
Her-2 inhibitor  
0.218  0.242  0.23  0.24  0.291  
0.212  0.241  0.225  0.236  0.284  
0.215  0.2415  0.2275  0.238  0.288  
 
Amount of proteins (mg in 10 ml)  (ug in 10 ul) 
 
27.5641  30.96154  29.166667  30.51282  36.8589744  
Amount of proteins (µg in 20 µl)  
55.12821  61.92308  58.333333  61.02564  73.7179487  
Volume of loading (µl)  
control  10 μM Citicoline  10 μM Citicoline 
+ 5μM Her-2 
inhibitor  
FGF-2  FGF-2 + 5μM 
Her-2 inhibitor  
14.51163  12.91925  13.714286  13.10924  10.8521739  
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Protein Estimation from hCMEC/D3 cell lysate for pHer-2  
                                                                                  Bovine Serum Albumin (BSA)  
O.D. 590 nm (standard curve)  BSA at 1mg/ml  
BSA (mg)  O.D. 590 nm  Mean  
0  0  0  0  BSA (µg)  Mean  
10  0.140  0.029  0.0845  0  0  
20  0.165  0.271  0.218  10  0.0875  
40  0.518  0.482  0.5  20  0.1505  
40  0.268  
 
 
  
control  10 μM Citicoline  10 μM Citicoline + 
1μM Her-2 inhibitor  
10 μM Citicoline + 
5μM Her-2 inhibitor  
0.23  0.228  0.179  0.183  
0.194  0.199  0.152  0.150  
0.212  0.2135  0.1655  0.167  
Amount of proteins (mg in 10 ml)  (ug in 10ul)  
27.17949  27.37179  21.217949  21.34615  
Amount of proteins (µg in 20 µl)  
54.35897  54.74359  42.435897  42.69231  
Volume of loading (µl)  
control  10 μM Citicoline  10 μM Citicoline + 
1 μM Her-2 
inhibitor  
10 μM Citicoline + 
5 μM Her-2 
inhibitor  
14.71698  14.61358  18.851964  18.73874  
 
 
 
